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ABSTRACT OF DISSERTATION

ADDITIVES TO CONTROL MECHANICAL PROPERTIES AND DRUG DELIVERY OF INJECTABLE
POLYMERIC SCAFFOLDS
In situ forming implants (ISIs) are popular due to their ease of use and local drug delivery
potential, but they suffer from high initial drug burst, and release behavior is tied closely to
solvent exchange and polymer properties. Additionally, such systems are traditionally viewed
purely as drug delivery devices rather than potential scaffold materials due to their poor
mechanical properties and minimal porosity. The aim of this research was to develop an
injectable ISI with drug release, mechanical, and microstructural properties controlled by microand nanoparticle additives.
First, an injectable ISI was developed with appropriate drug release kinetics for
orthopedic applications. Poly(β-amino ester) (PBAE) microparticles were loaded with simvastatin
or clodronate, and their loading efficiency and drug retention after washing was quantified.
Drug-loaded PBAE microparticles and hydroxyapatite (HA) microparticles were added to a
poly(lactic-co-glycolic acid) (PLGA)–based ISI. By loading simvastatin into PBAE microparticles,
release was extended from 10 days to 30 days, and burst was reduced from 81% to 39%.
Clodronate burst was reduced after addition of HA, but was unaffected by PBAE loading.
Scaffold mass and porosity fluctuated as the scaffolds swelled and then degraded over 40 days.
Next, the mechanical properties of these composite ISIs were quantified. Both microand nanoparticulate HA as well as PBAE microparticle content were varied. Increasing HA
content generally improved compressive strength and modulus, with a plateau occurring at 30%
nano-HA. Injectability remained clinically acceptable for up to 10% w/w PBAE microparticles. Ex
vivo injections into trabecular bone improved both strength and modulus.
Lastly, HA-free ISIs were investigated for drug delivery into the gingiva to treat
periodontitis. Doxycycline and simvastatin were co-delivered, with delivery of doxycycline over 1
week accompanied by simvastatin release over 30 days. PBAE-containing ISIs exhibited higher
initial and progressive porosity and accessible volume than PBAE-free ISIs over the course of
degradation. Additionally, PBAE-containing ISIs provided superior tissue retention within a
simulated periodontal pocket. The ISIs investigated here have a wide range of potential
applications due to their flexible material and drug release properties, which can be controlled
by both the chemistry and concentration of various particulate additives.

KEYWORDS: Injectable tissue engineering scaffolds, biodegradable polymers, controlled drug
delivery, biodegradable hydrogels, in situ forming drug delivery implant
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Chapter 1 Introduction
In situ forming implants (ISIs) made from poly(lactic-co-glycolic acid) (PLGA) have been
thoroughly investigated for drug delivery applications, and these systems have been
commercialized due to their simplicity and effectiveness as sustained, local drug delivery depots.
The release kinetics from these systems are generally controlled by modifying the polymer or
solvent used, but very little information is available on the impact that particulate additives may
have on the material properties and release kinetics. In particular, PLGA ISIs are not favored for
applications requiring tissue ingrowth or mechanical support because their microarchitecture and
mechanical

properties

are

inferior

to

pre-formed

scaffolds.

Here,

composite

PLGA/hydroxyapatite/hydrogel ISIs were developed for orthopedic applications, and
PLGA/hydrogel ISIs were also further investigated for soft tissue applications.
Chapter 2 provides a brief history of synthetic biodegradable polymers used for drug
delivery, and includes properties of some of the most popular materials. Then, the applications
for these materials are discussed, and particular focus is placed on micro- and nanoparticle
systems, as well as the different types of ISIs. Next is an overview of two conditions that were
targeted in this research – osteonecrosis of the femoral head and periodontitis. The specific aims
of this dissertation conclude Chapter 2.
Chapters 3 and 4 are both related to the development of a locally injectable PLGA ISI
suitable for orthopedic applications. The work in Chapter 3 is devoted to quantifying the effects
of hydrogel and hydroxyapatite additives on drug release from a PLGA ISI. A significant portion of
this chapter focused on developing drug-loaded, hydroxyapatite-coated, hydrogel microparticles.
The objective of this chapter was to demonstrate that particulate additives could modify release
kinetics and provide a suitable microarchitecture for trabecular bone augmentation. Chapter 4
focused on the effects of hydroxyapatite and hydrogel particles on the material properties of the

1

system. Specifically, mechanical properties and injectability were quantified, and injection into
artificial bone and ex vivo bone samples were used to demonstrate feasibility of the system as a
mechanically supportive, injectable scaffold.
In Chapter 5, PLGA ISIs containing a high concentration of hydrogel microparticles were
investigated for soft tissue applications, and the periodontal pocket was considered the target
tissue. Here, hydrogels were processed into microparticles using a wet grinding technique without
using hydroxyapatite additives. The purpose of adding hydrogel was to improve the space-filling,
microarchitecture, and co-delivery of an antibiotic and osteogenic drug. The objective of this
chapter was to show the potential of these materials for future consideration as tissue scaffolds.

Copyright © Paul Daniel Fisher 2014
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Chapter 2 Background and Significance
2.1. Synthetic biodegradable polymers for drug delivery
Biomaterials are classically defined, distinctly from drugs, as materials used to augment
or replace tissues or processes in the body. With the advent of synthetic, biodegradable polymers,
however, the line becomes blurred, as these materials are capable of blending the roles of
biomaterials and drugs into a single system [1]. The recognition that certain polymers containing
hydrolytically or enzymatically labile groups could be degrade naturally after implantation led to
a revolution in the field of drug delivery [2-8]. By incorporating drugs into a biodegradable
polymer matrix, spatial and temporal control of release kinetics was possible. As seen in Figure
2.1, the publication rate for biodegradable polymeric drug delivery systems has grown
exponentially since their first uses in the 1970s. This growth is due in no small part to the vast
array of synthetic polymer properties that can be controlled by both chemical syntheses and
material processing steps, resulting in an extremely versatile platform. Controlling and
understanding mechanisms by which these polymers degrade is important when designing or
choosing a material for drug delivery, because the degradation behavior influences drug release
rates and host response [9]. Some of the most popular materials and their potential applications
are presented in the subsequent sections, with an emphasis placed on their mechanisms and rates
of degradation.
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Figure 2.1. Annual publications containing the search terms “polymer” and “drug delivery.” Via
PubMed.
2.1.1. Polyanhydrides
Polyanhydrides are named for the anhydride bonds that link repeating units of the
polymer backbone (Figure 2.2A), and were originally synthesized in the early 1980s with the
objective of matching polymer degradation rate to drug release [10]. The anhydride bonds can be
hydrolyzed to produce dicarboxylic acids, and these materials degrade through surface erosion,
as the water uptake rate is generally far lower than the rate of surface chain scission [11]. As a
result of this degradation mechanism, linear drug release rates that closely match the material
degradation rate can be achieved [10, 12]. Since the bulk of the polymer does not appreciably
hydrate as it degrades, processing methods that affect the microstructure or the implant
geometry can strongly influence degradation kinetics by limiting or increasing the accessible
surface area [13, 14]. Copolymers of polyanhydrides are also used to control the properties of
these materials. For example, polyanhydrides copolymerized with more hydrophilic blocks can be
produced to accelerate degradation and drug release from months to hours [10, 13, 15-17], while
4

poly(anhydride-co-imides) possess mechanical properties more suitable for orthopedic
applications [18]. Polyanhydrides have been further modified via cross-linking to improve
mechanical strength [19, 20]. The incorporation of hydroxyapatite (HA) via surface-grafting can
promote bone cell attachment, and homogeneously incorporated HA can improve mechanical
properties [20, 21]. Polyanhydrides have exhibited good biocompatibility in animal in vivo studies,
with no observed toxicity, inflammation, or other adverse effects noted after implantation in a
variety of tissues [22-25]. The FDA first approved their use in 1996 in the form of Gliadel®, a
polyanhydride wafer loaded with chemotherapeutic carmustine, which is placed directly onto
brain tissue after removal of cancerous tumors.
2.1.2. Poly(lactic-co-glycolic acid)
The most well-characterized and prevalent biodegradable polymers in drug delivery are
composed of lactic or glycolic acid subunits, forming poly(lactic acid) (PLA), poly(glycolic acid)
(PGA), or poly(lactic-co-glycolic acid) (PLGA) (Figure 2.2B). Investigation of these polymers began
in the 1970s with PLA [3, 26, 27]. Because the monomers in PLA possesses methyl side groups,
optically pure, semicrystalline polymers made from either D or L enantiomers can be produced,
but PLA is most commonly used in drug delivery in amorphous form as the product of a racemic
mixture [28]. PGA is highly crystalline, though it is hydrolyzed rapidly compared to PLA due to its
more hydrophilic nature, and as a homopolymer was popularized as the first biodegradable
synthetic suture, Dexon® [29]. PLGA is generally amorphous, and degradation times are highly
dependent on the lactide:glycolide ratio [29-32]. As with most degradable polymers, the
degradation rate also decreases with molecular weight [33]. PLGA containing a 50:50
lactide:glycolide ratio degrades most rapidly, and degradation time can be modified by varying
molecular weight, hydrophilicity of the chain end species, or the lactide:glycolide ratio [33, 34].
PLGA, PLA, and PGA are primarily bulk-degrading because the polymer chains are hydrophilic
5

enough to allow water penetration before surface erosion occurs, so a progressive molecular
weight decrease occurs throughout the material [32]. Chain scission eventually produces lactic
and glycolic acid, both of which are endogenously produced during metabolic processes, and
soluble acidic oligomers may autocatalyze degradation [35, 36]. PLA and PLGA are used in many
commercial drug delivery systems, including antibiotic delivery (Atridox®, Arestin®), hormone
therapy (Nutropin®), and cancer treatment (Lupron Depot®, Trelstar Depot®, Eligard®).
2.1.3. Poly(caprolactone)
Poly(caprolactone) (PCL) is a biodegradable, semi-crystalline polymer characterized by its
hydrophobicity, long degradation time, and low melting point (Figure 2.2C). PCL was one of the
earliest polymers investigated as a degradable biomaterial, and was originally tested as a
biodegradable alternative to silicon rubber implants for long-term delivery of contraceptives in
the 1970s [5, 37]. However, its usefulness as a homopolymer was limited due to its 2-4 year
degradation time [38]. Because it is easily blended or copolymerized, PCL is often used to produce
copolymers or polymer blends with versatile rheological, viscoelastic, and drug release properties
that depend on the ratios of each component [39-43]. The glass transition temperature of PCL is
around -60˚C, meaning PCL is far more flexible and less brittle than PLGA and PLA at ambient and
physiological temperatures, which can improve physical properties of blends and copolymers [4446]. Additionally, its low melting temperature (approximately 60˚C) makes PCL one of the more
workable materials, so it is a popular choice for 3-D printing, extrusion, and melt blending [4750]. Amphiphilic copolymers of PCL and poly(ethylene glycol) (PEG) or other hydrophilic
components have been investigated as solid particles, hydrogels, or micelles, with the highly
hydrophobic PCL regions appropriate for sustained delivery of hydrophobic drugs [51-53]. The
physical properties of PCL allow it to be easily blended with particle additives and formed into
scaffolds with complex geometries, and PCL composites containing HA or other bioceramics have
6

been extensively investigated for orthopedic applications, although their lower mechanical
properties limit their load-bearing potential [49, 54-57]. A block copolymer of PCL and PGA, now
marketed as Monocryl®, was developed to reduce the stiffness of resorbable PGA sutures.
2.1.4. Poly(ortho esters)
In the 1980s, poly(ortho esters) (POEs), along with polyanhydrides, were among the first
polymers specifically synthesized for drug delivery [58]. The ortho ester bonds (Figure 2.2D) result
in more hydrophobic polymer chains than carbonyl-containing polymers such as PLGA, slowing
water penetration and limiting hydrolysis to the polymer-water interface. This results in a pHsensitive, surface-eroding material that produces low-molecular weight, soluble byproducts,
although longer-degrading POEs will eventually become permeated with water. Degradation rates
can be further controlled by the incorporation of glycolic acid or other acidic species into the
polymer backbone to autocatalyze degradation [59-61]. Conversely, surface erosion can be
prolonged by incorporating basic excipients with poor water solubility to stabilize the polymer
and prevent water imbibition [62]. During synthesis, the concentration of flexible diols and acid
diols used in the polymer backbone determines the glass transition temperature, so very brittle
or semi-solid POEs can be easily produced [63]. The latest generation of POEs have been
specifically investigated as intraocular delivery systems because they are a viscous, easily
injectable liquid at room temperature yet still provide erosion-based drug release [64, 65].
Because POEs are surface-eroding, they offer an advantage over PLA and PCL because smallmolecule, hydrophilic drugs can be released concomitantly with degradation as long as a
stabilizing excipient is used [66].
2.1.5. Poly(β-amino esters)
Poly(β-amino esters) (PBAEs) are a class of biodegradable polymers that are synthesized
through a condensation reaction between a diacrylate and a primary amine (Figure 2.2E) or
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secondary-secondary diamine [67, 68]. This initial reaction occurs through a step-growth
polymerization process, and a molar excess of diacrylate will produce acrylate-terminated
macromers [69]. These macromers can be cross-linked using free radical initiated chain-growth
polymerization to form hydrogels that can biodegrade at their ester bonds [69-71]. Many factors
determine the degradation rate and swelling behavior of these hydrogels in aqueous
environments, including diacrylate and amine chemistry, macromer synthesis time and
temperature, and cross-link density [69-71]. PBAEs have been extensively investigated for their
potential in DNA therapy. For example, PBAEs incorporated into PLGA microparticles were shown
to improve loading efficiency and delivery of plasmid DNA, preserve integrity of the delivered
plasmid DNA, and improve transfection efficiency [72-74]. Microparticulate copolymers of PBAE
and PEG have been investigated for pH-sensitive delivery of drugs to cancer cells [75-77], and
PBAE hydrogels have been investigated as both passive porogens and drug delivery vehicles [7882].
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Figure 2.2. Chemical structures of common synthetic biodegradable polymers. A) Polyanhydride.
B) Poly(lactic-co-glycolic acid). C) Poly(caprolactone). D) A simple ortho ester. Poly(ortho esters)
tend to contain repeated cyclic units and therefore have a variety of possible structures. E) Poly(βamino ester) synthesized using a primary amine.
2.2. Injectable drug delivery systems
As biodegradable polymers gained traction as versatile drug delivery platforms, research
began to focus on improving the structure of these materials to simplify implantation and take
advantage of their long lifespan in vivo. Pre-formed, monolithic implants require surgical
implantation at the treatment site, and this approach is undesirable or even impossible for
targeted treatments such as drug delivery to intratumoral or intraosseous tissue. Two distinct
approaches to this problem are discussed below. First, drug-loaded polymeric micro- or
9

nanoparticles allow targeted delivery of biodegradable polymers via simple injection. Second,
injections containing drug-loaded liquid precursors designed to solidify in situ permit formation
of a monolithic implant at the injection site.
2.2.1. Micro- and nanoparticle delivery
Micro- and nanoparticles can be synthesized using a variety of techniques. Most
commonly, the polymer is dissolved in an appropriate solvent, and is subjected to a series of
emulsion steps that both entrap drug and stabilize spherical polymer droplets as they solidify
during solvent evaporation. For hydrophilic drugs, a water/oil/water double emulsion technique
is used. First, an aqueous drug solution is dispersed in the polymer/solvent phase (W1/O emulsion
1). Next, the W1/O phase is emulsified in a second aqueous phase, creating a W1/O/W2 emulsion,
and solid particles can be created through solvent removal. Frequently, surfactants are used to
stabilize these emulsions, preventing collapse or coalescence of particles prior to solidification.
For hydrophobic drugs, a single emulsion technique is sufficient, with the drugs added directly to
the polymer phase, skipping the W1/O emulsion. Particle size can be controlled by adjusting the
solvent:water ratios, the surfactant content, temperature, and stirring parameters throughout
the process [83-87].
Microparticles can be created from films or slabs of material by simple grinding followed
by sieving to the desired particle size, although this works best for weak, brittle materials.[88]
Stronger materials are difficult to mechanically break apart, while soft or sticky materials such as
PBAE hydrogels will re-aggregate during the grinding process, necessitating a powder additive to
act as a dispersant. For particles that swell in water or other solvents without degrading quickly,
drugs can be more easily loaded after particle formation by swelling the particles in a drug solution
followed by solvent removal [81, 89-91]. This list of methods is by no means exhaustive – many
other techniques have been developed to create drug-loaded micro- and nanoparticles beyond
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these popular few listed, including spray drying [92-95], hot melt microencapsulation [96], phase
inversion microencapsulation [97], non-aqueous solvent removal [98],

and interfacial

polymerization [99, 100].
One major advantage of using a microparticle carrier is that particles can easily be injected
as a powder or aqueous suspension to the target site. For example, Arestin® is the product name
of a PLGA microparticle system, approved in 2001, containing the antibiotic minocycline. Arestin
is injected as a powder directly into periodontal pockets to treat infection, and can achieve up to
21 days of continuous drug release. Similarly, Lupon Depot ® is another PLGA microsphere-based
system that was FDA-approved in 1989 for the treatment of prostate cancer, and is capable of
delivering leuprolide acetate for 30 days. However, the properties of micro- and nanoparticles do
not always behave consistently with monolithic implant degradation and release kinetics. First,
particles have a much higher surface area to volume ratio, and thus the rate of water permeation
is increased. For surface eroding polymers such as poly(anyhydrides) and poly(ortho esters), this
means a faster, but generally still linear, release rate occurs since there is a larger polymer:water
interface for a given mass of material. For bulk degrading polymers such as PLGA, this means a
burst effect is often seen as the material hydrates much more rapidly, and diffusive release is
accelerated due to the smaller diffusion distance required to escape the material [101].
2.2.2. In situ forming implants
Compared to micro- or nanoparticle systems, in situ forming implants (ISIs) are simpler,
with fewer and less costly fabrication steps, and 100% encapsulation efficiency [102, 103]. The
principle underlying all ISIs is that a precursor solution or mixture can be injected at the treatment
site, and this mixture can be induced or will passively adopt a solid form, resulting in a monolithic
delivery system at the site of injection. Typical shortcomings of such systems include the
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propensity for burst release during the solidication period, toxicity of any additives required for
solidification (solvents, heat, or initiators), and heterogeneity of the ISI microstructure [102, 103].
2.2.3. Thermoplastics
Thermoplastics used as ISIs are polymers with a relatively low melting point, which
enables them to be injected as a melt and solidify upon cooling to body temperature.
Thermoplastics are an appealing choice for ISI because no solvents or chemical initiator is required
to solidify. Initial attempts to develop a thermoplastic ISI focused on block copolymers of PEG and
PLA and blends of L-PLA and PCL, however these materials exhibited melting or glass transition
points around 60˚C, which can cause pain, tissue necrosis, and scar tissue formation [104].
Additionally, such systems exhibited slow release, with less than 50% drug released by 30 or 60
days, depending on the material. Blending PCL with methoxyPEG was able to reduce the melting
temperature [105]. Poly(ortho esters) have also been investigated as thermoplastic ISIs, because
low-molecular weight POEs can be created with low viscosity at ambient temperatures [106]. POE
ISIs have been copolymerized with PLA or PGA to accelerate degradation and allow autocatalysis
of hydrolysis [107]. Thermoplastics have been most thoroughly investigated for drug delivery into
tumors because the local hyperthermia can be utilized as treatment, rather than a disadvantage.
2.2.4. Sol-gel transitioning materials
Sol-gels refer to materials that undergo a solution to gel phase transition due to a rise in
temperature that shifts the hydrogen bonding equilibrium from water-polymer to polymerpolymer [108]. The temperature at which this transition occurs is referred to as the lower critical
solution temperature (LCST), and this kinetics with which this phenomenon occurs can affect the
initial drug burst [109]. Poly(N-isopropyl acrylamide) (PNIPAAM) is one of the most studied solgels due to its rapid phase transition and its natural LCST of 32˚C, which can be adjusted to 37˚C
through additives [110-112]. Unfortunately, cell toxicity and platelet activation hinder PNIPAAM
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as a potential implantable material, and it must be copolymerized to become biodegradable [113,
114]. Copolymerizing PNIPAAM with known biodegradable species can allow hydrolytic
degradation into oligomers small enough to be cleared [115, 116]. Poly(ethylene oxide) (PEO) and
poly(propylene oxide) (PPO) have been investigated in the form PEO-PPO-PEO

triblock

copolymers, called Poloxamers, which undergo the sol-gel transition at a temperature dependent
upon the polymer concentration [117]. Most popular in this family of copolymers is Poloxamer
407 (Pluronic® F127), which has been well-tolerated after implantation in animals [118, 119].
However, Pluronic® F127 tends to disintegrate rapidly, limiting release to hours or days, and the
gel transition temperature and rate is susceptible to additives, including drugs [120, 121]. PCLPEG copolymers and PEG-PLGA-PEG triblock copolymers have been investigated because the
gelling temperature is easily controlled by varying PEG content, and have garnered interest due
to their low observed toxicity [122-124].
2.2.5. Cross-linking systems
In situ cross-linking systems differ from the previous in situ forming materials because an
additional stimulus is required to promote solidification. The stimulus can be heat, light, an ionic
species, or a reactive chemical [102]. Thermosets, which require heat as well as a chemical
initiator, are cured irreversibly as the cross-linking reaction proceeds. These systems have many
safety considerations before they can be considered, including heat generated, free radical
production, and toxicity of the monomers present in the prepolymer [103]. As such, relatively
little academic research is available on thermosets as biodegradable ISIs for drug delivery
applications, though several patents have explored the concept [125-127]. Photocrosslinked
polymers are advantageous because they can be rapidly polymerized via fiber optic cables
inserted during the injection, or by a penetrating light source, without excess heat needed.
Similar, non-degradable photocrosslinked materials have historically been used in dentistry for
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many years [128]. An ISI created by cross-linking a PEG-containing, acrylate-terminated polymer
with the photonitiator 2,2-dimethoxy-2-phenylacetophenone (DMPA), resulted in hydrogels with
significant tensile strength that released the (now discontinued) antibiotic sulfamethoxazole over
3 days [129]. PLA modified to allow cross-linking has been researched as an orthopedic material,
and PEG-based cross-linked hydrogels have been developed for protein release [130, 131].
Photocrosslinked polymers can be difficult to fully polymerize, because irregular geometry and
the presence of tissue limits light penetration, and just as in thermally cross-linked polymers, the
generation of free radicals can have toxic side effects. Furthermore, short-wavelength UV
irradiation rapidly damages tissues and is a known carcinogen, though even long-wave UV sources
are potentially carcinogenic [132]. Chemically cross-linked polymers begin polymerizing
immediately after addition a cross-linking reagent to the prepolymer, and as such are unique
among these in situ forming systems because they have a setting time that begins prior to
injection. Thiol-containing, PEG-based polymers were cross-linked into hydrogels within 3
minutes using a divinylsulfone-based cross-linking reagent, and these hydrogels were capable of
releasing a model protein, bovine serum albumin, for 20 days [133]. For chemically cross-linked
ISIs, monomer and initiator toxicity are of concern because the process generally proceeds more
slowly than thermal- or photocrosslinking, which can allow these species to leach out of the
injectate. Physically cross-linked materials are unique in that instead of creating covalent crosslinks via an initiator, the prepolymer forms strong physical associations that cause solidification.
Although not a synthetic material, one of the best examples of these materials is alginate, which
can utilize divalent cations (typically calcium) to form a physically cross-linked gel from a precursor
solution. Generally, physiological conditions do not have sufficient calcium concentrations to
promote gelation, so calcium can be co-delivered in temperature-sensitive vesicles that release
calcium at body temperature, resulting in gelation shortly after injection [134, 135]. However,
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because the vesicles had poor shelf-stability, the formulation would gradually gel prematurely as
calcium was slowly released even at low temperatures. An interesting application for injectable
alginate systems is ocular drug delivery, because fluids in the eye possess sufficient calcium
chloride concentrations to permit gelation. Such a system was able to release pilocarpine, a
glaucoma treatment, over 24 hours [136]. Degradation of alginate can be unpredictable because
these hydrogels are sensitive to ionic and pH fluctuations.
2.2.6. Solvent exchange
Phase inversion occurs when a hydrophobic polymer dissolved in a water-miscible solvent
is introduced to an aqueous environment. This process is appealing for drug delivery systems
because the formulation is quite simple, and a wide variety of polymers can be utilized. A drug is
freely mixed into the dissolved polymer, and upon injection, the polymer immediately begins to
precipitate, entrapping drug in the solid phase as solvent exchange occurs. However, drug release
is characterized by an initial burst, especially for hydrophilic drugs, because drug can easily escape
during solvent exchange prior to complete solidification. PLA and PLGA are the two most popular
materials for phase inverting ISIs, and they are used in two FDA-approved delivery systems –
Atridox® and Eligard®. Many factors can influence the microstructure and drug release kinetics of
these ISIs: choice of polymer, polymer concentration and molecular weight, water miscibility of
solvent, and the size and hydrophilicity of the drug [137-141]. Generally, highly water-miscible
solvents such as N-methyl-2-pyrrolidone (NMP) are used because they allow rapid solidification,
yet this also contributes to higher burst release and a hetereogeneous microstructure, as surface
solidification occurs more rapidly [142]. Such systems exhibit elongated pores oriented radially
towards the surface, as well as an outer, low-porosity “skin” layer [137, 143]. Solvents with low
miscibility, such as benzyl benzoate or triacetin, cause lower burst and longer release periods as
well as more spherical, uniformly-distributed pores [137, 143]. There is evidence that these
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hydrophobic solvents may lead to the formation of an intermediate gel phase that gradually
solidifies [144, 145]. However, these slow-forming systems can take days or weeks to solidify, and
the semisolid implants with liquid cores can rupture if they are subjected to stresses. Increasing
polymer concentration slows drug release by forming a thicker “skin” layer, which hampers drug
diffusion as well as solvent exchange [142, 146]. Increasing polymer concentration will also
increase the viscosity of the system and slow solidification. Hydrophilic, small-molecule drugs are
the most challenging to control in these systems, because a large initial burst occurs during
solvent exchange, while proteins or hydrophobic small molecule drugs are entrapped in the solid
phase more efficiently and exhibit lower burst. ISIs formed by phase inversion comprise the focus
of the subsequent chapters.
2.3. Clinical applications for in situ forming systems
ISIs can be utilized in two different ways: either the ISI can be injected with the objective
of sustained, systemic delivery of drugs, or it can be injected into a target tissue to provide a local
treatment with limited systemic availability. A specific focus will be made on solvent-exchange
systems, as these are the foundation of this work, and several commercially available and
preclinical forms are currently available. Because PLGA is present in many FDA-approved
formulations, its clinical safety has been well-established, and the solvents used are considered
nontoxic, with side effects limited to mild irritation [147]. By comparison, other in situ forming
materials are still in their infancy, with many unknowns including material stability, in vitro vs in
vivo behavior, and potential side effects. In particular, factors such as heat, free radicals, and
potentially toxic polymer precursors or initiators are all components of other systems that require
extensive research before they can be considered for clinical applications.
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2.3.1. Systemic treatments
Systemic drug delivery can achieved from ISIs by injection into a tissue where the released
drug can freely enter circulation. The subcutaneous route is most popular because it is easily
accessed with a simple injection, and there is sufficient circulation and fluid flow to distribute the
drug and clear the polymer as it degrades. ISIs for systemic drug delivery are advantageous
because they can provide sustained delivery of a drug from a single injection (typically monthly),
while a simple drug solution may require daily injections to maintain a therapeutic concentration
[102]. Two technologies, both based on solvent exchange, are commercially available or in clinical
trials. Eligard® is an FDA-approved treatment for advanced prostate cancer, which is composed
of a PLGA solution in NMP that is mixed with leuprolide acetate prior to subcutaneous injection
[148]. Previous treatments required daily subcutaneous injection of a leuprolide solution, while
Eligard® is available in 1-month, 3-month, and 6-month formulations, with longer-lasting
formulations containing PLGA at higher concentrations and with larger lactide:glycolide ratios. For
patients with advanced prostate cancer, these infrequent treatments are an effective palliative
treatment requiring minimal hospitalization time. Another systemic treatment utilizing solvent
removal from PLGA ISIs is Relday™, which recently completed phase I clinical trials. Relday™
delivers risperidone from a subcutaneous or intramuscular implant in a once-monthly injection
for the treatment of schizophrenia and bipolar disorder.
2.3.2. Targeted therapies
Closer attention will be paid to targeted injections to treat specific tissues with local
dosages, as ISIs offer potential advantages over existing technologies. Because they solidify upon
injection, ISIs can be retained within the target tissue, while drug solutions or microparticle
suspensions can potentially be cleared from the injection site due to natural fluid flow. Limiting
systemic dosages is a major goal for modern targeted drug delivery systems, because it enables
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lower overall drug loading (reducing cost), and reduces or eliminates side effects. As an example,
expensive and potent growth factors such as bone morphogenetic protein 2 (BMP-2) can have
severe side effects such as heterotopic ossification and tumor formation when they reach tissues
outside the treatment area [149, 150]. A solid delivery depot could greatly reduce both treatment
costs and the chance of these serious adverse effects by efficiently delivering drug only to the
target tissue. This concept, in the form of a solvent-exchange ISI, has been explored in numerous
research articles as well as one commercial product designed for the treatment of periodontitis.
2.3.3. Periodontitis
Periodontitis is a term for inflammatory diseases oral tissue, specifically gingival tissue,
alveolar bone, and ligamentous tissue all involved in tooth support [151]. In the United States
alone, 48% of adults suffer from chronic periodontitis, and it is estimated that 90% of the world’s
population is affected [151, 152]. Beyond its effects on oral health, periodontitis has also been
implicated in development of systemic conditions such as cardiovascular disease, stroke, and
diabetes [153, 154]. An initial buildup of bacteria that is not addressed properly by oral hygiene
will eventually form larger colonies in gingival pockets residing below the gingival sulcus. These
pockets, if left untreated, become periodontal pockets, in which the fibrous attachment of
gingival tissue to the tooth is destroyed and destruction of alveolar bone occurs [151]. Bacteria
adhering to the tooth surface can form a biofilm, called dental plaque, which begins as a sticky
layer that hardens within 48 hours [155]. Once the plaque has hardened, it requires professional
cleaning to reliably remove, and can act as a barrier that limits drug penetration to the underlying
bacteria. The combination of a periodontal pocket and plaque barrier protect the bacteria and
allow the infection to flourish, and the surrounding tissues exhibit inflammation and resorption
due to the spreading bacterial front. Ultimately, as the fibrous tissue and alveolar bone is
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destroyed, tooth loosening and loss will occur, and severe infections can spread beyond the oral
cavity if they reach the bloodstream [151].
Treatment of periodontitis begins with a proper oral hygiene, which can halt the disease
at its early stages [156]. Advanced periodontitis requires a deep, professional cleaning, termed
scaling and root planing. Scaling is the removal of tartar (hardened plaque) from the tooth surface,
and root planing is the process of smoothing the tooth root and removing infected tissue [157].
Together, these techniques are effective at combatting periodontitis, though infections can still
persist and the missing tissue often fails to regenerate. Antibiotics are therefore frequently used
as an adjuvant therapy in the treatment of advanced periodontitis where persistent infection can
occur [158, 159]. Tetracyclines such as doxycycline are the most popular antibiotic for this disease,
because they effectively inhibit the growth of A. actinomycetemcomitans, one of the most
common bacteria involved in aggressive periodontitis, and are also lethal to other bacterial
species [160, 161]. Doxycycline also has anti-matrix metalloproteinase (MMP) activity, therefore
slowing or preventing the resorption of connective tissue [161-163]. This secondary anti-MMP
effect occurs even at subantimicrobial doses, and has been shown to improve outcomes when
combined with scaling and root planing [164]. Further, there is evidence that doxycycline has antiinflammatory and anti-bone resorptive properties [165-167]. Looking towards the future, an ideal
treatment for periodontitis can be envisioned, in which local delivery of an antibiotic is coupled
with restorative drugs (for example, an osteogenic agent to help regenerate lost alveolar bone).
In cases where alveolar bone loss is extensive, tissue grafts as well as synthetic scaffolds have
been employed to guide bone regeneration [168, 169]. Therefore, a single injection that provides
drug delivery as well as scaffold potential can serve multiple purposes as a periodontitis
treatment. Currently, a solvent removal-based ISI, Atridox®, is commercially available as a
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sustained local doxycycline treatment that is injected directly into the periodontal pocket after
scaling and root planing.
2.3.4. Osteonecrosis of the femoral head
Osteonecrosis of the femoral head is the death of bone tissue in the proximal femoral
epiphysis, generally due to an interruption in blood supply. An estimate from the 1990s indicated
that osteonecrosis of the femoral head affects over 10,000 new patients each year in the United
States, and is also responsible for more than 10% of all hip arthroplasties annually [170]. A more
recent study in Korea found that the incidence of confirmed diagnoses nearly doubled between
2002 and 2006, with prevalence rising from 20 per 100,000 to 38 per 100,000 [171]. There are
many identified risk factors, including chronic steroid use, alcohol use, trauma, and smoking, and
up to 10-25% of cases are idiopathic [172]. Most of the blood supply to the femoral head comes
from the large branch of the medial femoral circumflex artery and smaller branches of the lateral
femoral circumflex artery. The superior and inferior gluteal arteries and the ligamentum teres also
contribute to the epiphyseal vasculature [173]. Though the exact mechanism causing progression
of osteonecrosis is unclear, it is believed that infarction in some of these blood sources can lead
to cell necrosis as well as pathological apoptosis of osteoblasts and osteocytes [174]. As a result,
the balance between osteoclast and osteoblast activity is disrupted, resulting in proportionally
more resorption. Because the femoral head is weight-bearing, microfractures due to
osteonecrosis can easily propagate and lead to structural collapse. Osteonecrosis in the femoral
head begins asymptomatically, then appears as a small, crescent-shaped region of radiolucency
adjacent to the weight-bearing region at the articular surface. This region progresses to a
flattened or otherwise deformed femoral head as the bone collapses, and this process is
associated with pain and stiffness in the joint [170, 175-177]. If osteonecrosis is diagnosed in the
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early stages, before collapse has occurred, there are surgical options that have had varying
degrees of success.
The most common treatment for osteonecrosis of the femoral head is core
decompression, which has a success rate inversely proportional to the amount of necrosis, with
“success” determined as halting or reversing the progression of the disease [178]. However,
patients with successful intervention are still subject to recurrence, as well as elevated rates of
osteoarthritis and eventual arthroplasty later in life [179, 180]. A major issue with the treatment
options for osteonecrosis is that a diagnosis is frequently not made until the condition has already
progressed to a stage where collapse is inevitable. Core decompression is thought work by
alleviating high pressure and promoting a bone healing response to the removed tissue, but it
does not rescue mechanically compromised bone. Recent research has focused on
pharmaceutical intervention using targeted delivery systems to treat osteonecrosis. Patients
receiving systemic bisphosphonate treatments to inhibit resorption had better outcomes if their
disease was still in the early stages, although follow-up studies have had mixed results regarding
incidence of arthroplasties within two years following treatments [181-184]. Contemporary
research has utilized a targeted injection of bisphosphonate solution to prevent systemic
exposure, as well as the addition of BMP-2 to the injection to promote osteogenesis, with
promising results.[185, 186] However, there were issues with heterotropic ossification, indicating
that the injection was not fully retained within the femoral head [186]. Recently, an injectable
system for co-delivery of clodronate and simvastatin was also developed for the treatment of
pediatric idiopathic osteonecrosis [90]. Clodronate is a bisphosphonate whose mechanism of
action causes apoptosis of osteoclasts, while simvastatin has recently been extensively studied
for its upregulation of BMP-2 to promote bone regeneration [187-190]. ISIs have not been
investigated for treatment of these diseases, and they traditionally have low porosity and poor
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mechanical properties. However, the femoral head is an interesting target tissue for ISIs because
it is a naturally constrained geometry, and the network of trabecular bone would require a liquid
injection for interpenetration of a scaffold. However, ISIs would require modification of the
microarchitectural and material properties in order to be considered as drug delivery scaffolds for
these intraosseous applications.
2.4. Significance and Objectives
The PLGA ISIs are approved for clinical use in their simplest form, with a single drug freely
mixed into the PLGA phase, and most research has focused on modulating release kinetics by
varying PLGA and solvent concentration or chemistry. However, incorporating micro- and
nanoparticle additives into the PLGA matrix may be able to influence drug release and mechanical
properties without modifying the polymer or solvent. Micro- and nanoparticle additives have
been incorporated into pre-formed implants to produce composite scaffolds with a wide range of
physical and chemical properties, and this approach allows a material as simple as PLGA to be
used as a drug delivery scaffold for soft tissue or orthopedic applications. It is important to note
that ISIs are currently considered simply as injectable drug depots, rather than functional scaffolds
that can aid in tissue regeneration, because there is very little control over the microstructure or
mechanical properties as they solidify. Conceivably, composite ISIs can be considered as drugdelivering scaffolds instead of simply as injectable drug depots. The objective of this research is
to develop a modular platform that is easily adapted to different drugs and tissues by varying
particulate additives. This research is divided into three separate aims, of which the first two focus
on development of a composite PLGA ISI for orthopedic applications, and the last of which seeks
to improve the properties of PLGA ISIs used in dental applications.
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2.5. Specific Aims
Aim 1: To characterize the drug release and microarchitectural properties of novel orthopedic ISI.
These composite PBAE-PLGA-HA ISIs were created by admixing drug-loaded PBAE hydrogel
microparticles and HA microparticles into a PLGA solution prior to injection. The potential of PBAE
and HA microparticles to modulate release of simvastatin and clodronate was investigated.
Aim 2: To demonstrate the feasibility of the orthopedic ISI from Aim 1 as a mechanically
supportive scaffold. The HA content and particle size were varied with the objective of creating a
material that is mechanically similar to trabecular bone. Injectability was quantified to ensure that
the injectable mixture could be handled in a clinical setting, and as a proof of concept, the mixture
was injected ex vivo into intact porcine femoral heads.
Aim 3: To develop a composite PBAE-PLGA ISI that is suitable for soft tissue applications such as
periodontal drug delivery in gingival tissue. PBAE content was increased compared to Aims 1 and
2, HA not used, and two different molecular weights of PLGA were considered. Co-delivery of
doxycycline and simvastatin was investigated. The development of porosity and the preservation
of microstructure and mechanical resilience throughout degradation was investigated, and the
goal of these experiments was to demonstrate the potential for these ISIs as tissue engineering
scaffolds for future studies.
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Chapter 3 Improved small molecule drug release from in situ forming poly(lactic-co-glycolic
acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles
This chapter reproduced from a published manuscript, “Fisher, P.D., P. Palomino, T.A. Milbrandt,
J.Z. Hilt, and D.A. Puleo, Improved small molecule drug release from in situ forming poly(lacticco-glycolic acid) scaffolds incorporating poly(beta-amino ester) and hydroxyapatite
microparticles. Journal of Biomaterials Science. Polymer Edition, 2014. 25(11): p. 1174-93.”
3.1. Introduction
Controlled drug delivery systems offer a variety of potential advantages over traditional
routes of administration, such as oral dosages and intravenous or subcutaneous injection of drug
solutions, due to their spatial and temporal control over drug release [191]. Traditional dosage
forms result in systemic circulation of drug, and the oral route is also subject to first-pass
metabolism [192]. Injections introduce a bolus of drug at high concentrations, and long-term
treatment requires repeated dosing, resulting in pulsatile concentration profiles [193].
Implantable drug-loaded scaffolds can be placed at the treatment site to minimize systemic
exposure and can be designed to control release kinetics by varying the chemical and physical
nature of the carrier [193, 194]. These systems, however, generally require a surgical procedure
to implant the device, and in the case of a non-degrading material, require a removal surgery. As
a result, significant effort in the drug delivery field has focused on injectable, biodegradable drug
carriers, such as in situ gelling, polymerizing, or precipitating systems [195, 196]. A space-filling
scaffold capable of forming into a biodegradable solid at the treatment site is an appealing option
because it can penetrate a tissue network to deliver drugs at a fixed location with minimal
invasiveness and no removal surgery.
Poly(lactic-co-glycolic acid) (PLGA) is an attractive material for an in situ forming delivery
system because it is already present in FDA-approved injectable products (Atridox® and Atrigel®
systems), it degrades hydrolytically, and its physical properties can be controlled by varying the
lactide:glycolide ratio, molecular weight, and end species [197]. PLGA is dissolved in a water24

miscible solvent and mixed with a pharmaceutical agent prior to injection to form a drug
suspension or solution. The resulting mixture is injected into the treatment site, where it
precipitates into a solid and gradually releases the drug [198]. These systems have been
investigated for protein release [146, 199] as well as small molecule drugs [200], and have
demonstrated biocompatibility [147].
Typically, injectable PLGA systems have a large initial burst release followed by sustained
release over a period of hours to weeks [195]. The magnitude of this burst release as well as
precipitation rate are both governed by the rate of solvent exchange [137, 139]. Therefore,
systems with lower initial burst tend to undergo slower solidification due to gradual solvent
exchange, while rapid precipitation corresponds to rapid solvent exchange and correspondingly
large burst. Release kinetics following the burst are primarily diffusive until degradation of the
polymer matrix becomes a contributing factor [139]. The burst can be reduced by increasing
polymer content of the solution, increasing polymer molecular weight, or changing to a less
water-miscible solvent [138, 195, 201]. However, increasing polymer content increases the
viscosity of the solution, slows precipitation, and leads to the formation of a low-porosity “skin”
around the scaffold [139, 202]. Increasing polymer molecular weight and/or hydrophobicity
increases degradation time [138], and choosing a less water-miscible solvent dramatically slows
precipitation [137, 201].
Incorporating drug-loaded microparticles into an injectable PLGA system may provide a
secondary means of controlling release kinetics. This concept has been previously investigated by
mixing PLGA microspheres containing plasmid DNA into the PLGA solution prior to injection [203].
PLGA microspheres will dissolve in the organic solvents used in the system, however, which
confers a time constraint on the mixing process and may be unsuitable for small molecule drugs
that can easily escape from partially dissolved microspheres. By instead utilizing crosslinked
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microparticles that will not dissolve in NMP but are still hydrolytically degradable, the utility of
the in situ forming PLGA system may be greatly expanded. Poly(β-amino ester) (PBAE) hydrogels
are formed via step growth polymerization of a diacrylate and an amine followed by free radical
crosslinking, and degradation time can be modified by changing the monomers to influence
crosslink density and hydrophilicity [69]. Recently, PBAE microparticle and nanoparticle systems
have been investigated for their drug delivery potential [75, 204, 205]. Incorporation of drugloaded PBAE microparticles into an injectable PLGA system has the potential advantage of
controlling and prolonging drug delivery while reducing initial burst.
Intraosseous injection in particular is a suitable application for an in situ forming system
due to the interconnected porous network of the trabecular bone that makes placement of preformed scaffolds difficult and removal surgery impossible. Injectable PLGA systems can
theoretically accommodate filler particles such as hydroxyapatite (HA) to influence
microarchitecture, mechanical properties, or osteoconductivity. N-methyl-2-pyrrolidone (NMP),
currently used in the FDA-approved Atrigel and Atridox delivery systems, is highly water-miscible
and provides rapid solidification. Additionally, NMP has been shown to promote bone
morphogenetic protein 2 (BMP-2) dependent alkaline phosphatase activity as well as reduce
osteoclast activity [206, 207]. Bisphosphonates, such as clodronate, are used to prevent bone
resorption via osteoclast apoptosis or inactivation [189]. Simvastatin is a drug that is primarily
used for its inhibition of 3-hydroxy-3-methylglutaryl coenzyme A to treat high cholesterol, but it
has recently been investigated for osteogenic applications due to numerous studies reporting that
simvastatin promotes bone formation via BMP-2 upregulation [190, 208].
Clodronate and simvastatin are both small molecule drugs, and therefore they are prone
to rapid release and high burst in a traditional in situ forming PLGA system. It was hypothesized
that an in situ forming PLGA system containing drug-loaded PBAE microparticles and HA filler
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would provide superior simvastatin and clodronate release kinetics compared to existing systems
using freely mixed drugs.
3.2. Materials and Methods
3.2.1. Materials
Poly(lactic-co-glycolic acid) (PLGA; 50:50 L:G, acid terminated, inherent viscosity 0.550.75 dL/g) was purchased from DURECT, Inc. (Birmingham, AL, USA). Simvastatin was purchased
from Haorui Pharma-Chem (Edison, NJ, USA). Clodronate, hydroxyapatite, 2,2-dimethoxy-2phenylacetophenone (DMPA), and N-methyl-2-pyrrolidone (NMP) were obtained from SigmaAldrich (St. Louis, MO, USA).
3.2.2. PBAE polymer synthesis
PBAE macromer was synthesized by reacting diethylene glycol diacrylate and
isobutylamine at a 1.2:1 diacrylate:amine molar ratio at 85oC for 16 hours. Macromer was stored
in an opaque vial under refrigeration until use. To create crosslinked hydrogels from macromer,
1 wt/wt% DMPA initiator dissolved in 50 wt/wt% ethanol was vortexed with macromer. The
mixture was then pipetted between two glass plates with Teflon spacers, sealed and clamped,
and then exposed to a UV flood source with an intensity of 12 mW/cm2 for 5 minutes to form a
crosslinked hydrogel slab. These PBAE hydrogel slabs were washed overnight in ethanol to
remove unreacted monomer and initiator, and then stored in a desiccator to remain dry until use.
3.2.3. PBAE particle formation and drug loading
PBAE microparticles were formed by grinding dry PBAE slabs with a mortar and pestle,
with HA added during the grinding process to coat particles and prevent aggregation. HA content
was preliminarily tested at 66 w/w % and 75 w/w % weight ratios, and 75% (50 v/v %) was chosen
due to ease of particle fabrication. PBAE particles were sieved to less than 250 μm, and larger
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particles were re-ground until all material was collected through the sieve. A Zeiss Evo MA 10
scanning electron microscope (SEM) (Carl Zeiss, Thornwood, NY) at 4 kV accelerating voltage was
used to visualize particle morphology, and a Quantax energy-dispersive x-ray spectroscopy (EDS)
detector was used for elemental analysis. A series of 10 microscope images of HA and PBAE
particles were analyzed using freely available ImageJ software to calculate mean particle size.
Simvastatin was either loaded into PBAE slabs prior to particle formation (pre-loaded) or
loaded directly into PBAE microparticles (post-loaded), and each method was assessed for loading
efficiency as well as the percentage of drug that was weakly bound to particle surface. Figure 3.1A
graphically represents the processing method for creating PBAE microparticles, as well as the
differences between pre- and post-loaded particles. Post-loaded particles were prepared by
dissolving simvastatin in ethanol at a concentration of 100 mg/mL and pipetting drug solution
over particles at a ratio of 2 µL per mg of particles. This ratio allowed particles to swell without
excess solution remaining, and expected drug loads were calculated under the assumption that
all drug solution was imbibed by the microparticles. Particles were lyophilized overnight, briefly
re-ground and sieved to break up aggregates, and stored in a vacuum chamber with desiccant.
Pre-loaded microparticles were prepared by immersing PBAE slabs in simvastatin solution,
allowing the hydrogel to swell for 24 hours, and then removing the hydrogel and lyophilizing
overnight to evaporate ethanol. Drug-loaded PBAE slabs were ground with 75 wt% HA into
particles and stored in a vacuum chamber with desiccant. Predicted values for drug loading using
the pre-loading method were obtained by calculating swelling of PBAE in solution based on mass
increase and assuming drug was homogeneously present in swollen hydrogels as well as
surrounding solution. The density and concentration of the drug solution was then used to
calculate expected drug loading based on mass change of the PBAE samples. Clodronate was
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loaded into separate batches of microparticles using an identical pre-loading technique with a 50
mg/mL clodronate solution in deionized water.
3.2.4. Measurement of drug loading into PBAE
Simvastatin loading into PBAE microparticles was measured by immersing drug-loaded
particles in ethanol, vortexing, and allowing the particles to swell for 24 hours. The mixtures
containing ethanol and swollen PBAE microparticles were then centrifuged, and supernatants
were analyzed using HPLC to detect simvastatin as described in 2.7 Measurement of drug
concentrations. Clodronate loading was measured with an identical technique using 50% ethanol,
and was detected by absorbance as described below. A mass balance indicated that all drug was
successfully removed from the particles during 24 hours of immersion in ethanol for simvastatin
or 50% ethanol solutions for clodronate, and subsequent immersions extracted no additional
drug. Loading efficiency was defined as the ratio of the total mass of drug loaded into the particles
to the initial mass of drug exposed to the particles.
In addition to loading efficiency, the percentage of drug present on the surface of particles
was determined by washing drug-loaded particles with 5 mL ethanol over a filter to remove
loosely surface-bound simvastatin or with 5 mL deionized water to remove loosely surface-bound
clodronate. The remainder of drug present in the bulk of the microparticles was extracted by
immersing particles for 24 hours in ethanol for simvastatin or 50% ethanol for clodronate. Drug
detected in the initial wash was deemed loosely bound to the surface of particles, while drug
detected after the 24 hour soak was determined to be imbibed into the bulk of the particles.
3.2.5. Formation of injectable scaffold system
PLGA was added to NMP and stirred overnight until fully dissolved to create a 20 wt/wt%
PLGA solution. Simvastatin-loaded PBAE microparticles pre-loaded using 100 mg/mL simvastatin
were added at 5 wt% and mixed homogeneously prior to injection. HA was also mixed
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homogeneously prior to injection to bring the final mixture to 30 wt% HA. Clodronate-loaded
PBAE microparticles pre-loaded with 50 mg/mL clodronate were added using an identical
technique. Samples without microparticles were prepared by freely mixing 1 wt% simvastatin or
clodronate into 20% PLGA solution to simulate a traditional in situ forming PLGA system. Figure
3.1B illustrates the differences between the proposed system and a traditional injectable system.
Simvastatin and clodronate were measured as described in 3.2.7. Measurement of drug
concentrations.

Figure 3.1. PBAE microparticle and injectable scaffold fabrication process. A) Technique for
formation of PBAE hydrogels and processing them into drug-containing pre- or post-loaded
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microparticles. B) Comparison of a traditional injectable PLGA system (right) to the proposed
system (left).
3.2.6. In vitro drug release
The scaffold mixture was injected dropwise through a 16 gauge, blunt-tipped dispensing
needle into PBS at 5% wt/vol. Upon contacting PBS, surface PLGA immediately began to
precipitate, forming semi-spherical scaffolds approximately 3 mm in diameter that sank to the
bottom of the vial. Samples were kept in an incubator at 37°C on a plate shaker for the duration
of the study. Supernatant was collected and replaced at each time point, and these samples were
preserved at 4oC until analysis. Clodronate release was measured for three loading conditions:
freely mixed clodronate without HA filler, freely mixed clodronate with HA filler, and clodronate
pre-loaded into PBAE microparticles with HA filler. Because PBAE microparticles were fabricated
with HA as a dispersing agent, drug release from loaded particles was not investigated without
HA filler. Simvastatin release was measured for three loading conditions: freely mixed simvastatin
without HA filler, freely mixed simvastatin with HA filler, and simvastatin pre-loaded into PBAE
microparticles with HA filler.
3.2.7. Measurement of drug concentrations
Simvastatin was measured on a Hitachi Primaide HPLC system equipped with a C18
column using a mobile phase composed of 70% acetonitrile and 30% water with 0.1%
trifluoroacetic acid at a flow rate of 1 mL/min, and peaks were observed at 240nm. Clodronate
from collected supernatants were measured using a Powerwave HT (Biotek; Winooski, VT, USA).
In vitro release supernatant was pipetted into a UV-grade 96-well plate (Greiner Bio-One,
Frickenhausen, Germany), and baseline absorbance was measured at 240 nm. On its own,
clodronate does not exhibit a distinct absorption peak, so concentration was measured by mixing
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supernatant with a solution of 1.5 mM copper sulfate and 1.5 mM nitric acid at pH 2 to form a
clodronate-copper complex that exhibits absorption at 240 nm [209]. A pilot experiment
confirmed that HA did not significantly interfere with clodronate readings in the working range.
3.2.8. Characterization of release kinetics
Drug release from polymeric systems is often analyzed using an adaptation of the Higuchi
model by Peppas et al., widely known as the power law, to characterize release kinetics [210]:
𝑀𝑡
𝑀∞

= 𝑘𝑡 𝑛

Here, Mt is the mass of drug at time t, M is the total mass of drug in the system,

(3.1)
𝑀𝑡
𝑀∞

represents

fractional release of drug at time 𝑡, 𝑘 is a constant encompassing scaffold and drug properties,
and 𝑛 is the release exponent used to characterize drug release. In the case of the spherical
geometry (consistent with scaffolds formed via dropwise injection), 𝑛 = 0.43 corresponds to pure
Fickian diffusion, 𝑛 =0.85 corresponds to pure case II (polymer relaxation-based) transport, and
values in between are combinations of the two, termed anomalous transport [210]. Plots of
𝑀

log 𝑀 𝑡 versus log 𝑡 were used to determine 𝑛 for each drug. The power law is applicable when
∞

𝑀𝑡
𝑀∞

< 0.6, so release data were truncated to below 60% cumulative release when calculating 𝑛.

3.2.9. Mass loss and degradation
The injectable scaffold system was prepared as described previously, using unloaded
microparticles. Non-destructive degradation analysis was performed on hydrated scaffolds in
order to observe the mass change of wet samples. Scaffolds were injected dropwise into PBS and
incubated at 37oC on a shaker for 80 days. Initial injected mass was recorded for each scaffold. At
intervals, scaffolds were removed from PBS, gently blotted dry, and weighed. Destructive analysis
of dried samples was used to analyze scaffold dry mass change. Scaffolds were injected dropwise
into PBS and incubated at 37ºC on a plate shaker until analysis. At each time point, scaffolds were
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lyophilized for 24 hours, and dry weight was measured. Lyophilized scaffolds were also scanned
using a Scanco MicroCT 40 (Scanco Medical, Switzerland) at 55 kV and 145 mA with 6 μm voxel
size. The built in bone trabecular morphometry tool was used to create 3D reconstructions to
visualize microarchitecture and quantify porosity and pore size at various time points during the
degradation process.
3.2.10. Statistical analysis
All data are presented as mean ± standard deviation. Release data were analyzed in JMP
10 software, using one-way analysis of variance (ANOVA) to determine differences between
release curves followed by Tukey-Kramer mean comparison tests as necessary. Comparisons
between individual pairs of samples for loading efficiencies were performed using a student’s
two-tailed t-test. Differences were considered significant for p < 0.05.
3.3. Results
3.3.1. Drug loading into PBAE particles.
Drug loading into PBAE increased linearly with drug solution concentration for simvastatin
(Figure 3.2A) and clodronate (Figure 3.2B and 3.2C). Clodronate became insoluble at 20 mg/mL in
50% ethanol, while the drug remained soluble through 100 mg/mL in DI water. At 100 mg/mL
clodronate, however, it was observed that hydrogel would swell to a greater degree and fracture
upon handling, leading to high variability between samples (Figure 3.2C), so 50 mg/mL clodronate
in DI water was used for future experiments. Simvastatin was loaded into gels or particles using a
100 mg/mL solution in 100% ethanol.
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Figure 3.2. Drug loading into PBAE hydrogel. A) Simvastatin loading after soaking in 100% ethanol
solutions for 24 hours. B) Loading after soaking in 50% ethanol clodronate solution for 24 hours.
C) Loading after immersion in aqueous clodronate solution for 24 hours. Data are mean ±
standard deviation (n=3).

34

HA possessed a mean particle diameter of 10 μm, while the PBAE particles produced by
grinding PBAE hydrogels together with HA had a mean diameter of 68 μm. PBAE microparticles
exhibited a composite structure consisting of spherical particles consistent with HA sizes
embedded in an amorphous material consistent with the hydrogel nature of PBAE (Figure 3.3A).
The spherical HA particles exhibited a rough, granular surface morphology, compared to the
smooth PBAE component. EDS elemental mapping showed calcium and phosphorous localized to
the spherical particles (Figure 3.3B). Point analysis of presumed HA and PBAE regions indicated
higher calcium and phosphorous levels in spherical HA particles, and higher carbon and oxygen
content in the PBAE region (Figure 3.3C). When these microparticles were immersed in a mixture
of 20% PLGA solution in NMP with 30 wt% HA added to simulate pre-injection conditions, they
underwent a 47% mass increase due to swelling (Figure 3.3D), with a 28% increase occurring
within 5 minutes.

35

36

Figure 3.3. Morphology, composition, and swelling of PBAE microparticles. A) SEM image of a
PBAE microparticle, with EDS performed on the highlighted portion. B) Top left: Region chosen
from (A) for EDS analysis, with arrows indicating points of spectral analysis performed in (C).
Bottom left: Composite overlay of calcium and phosphorous on that region. Top right: EDS
detection of calcium. Bottom right: EDS detection of phosphorous. B). C) EDS spectra of an HA
particle (blue) and PBAE (red). D) PBAE swelling kinetics expressed as a percentage of mass
increase in injection mixture (30 wt% HA mixed into 20% PLGA solution). Data are mean ±
standard deviation (n=3).
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Efficiency of incorporating simvastatin into post-loaded particles ranged from 52% to 77%
(Figure 3.4B), and efficiency ranged from 89% to 96% in pre-loaded particles (Figure 3.4D). A
surface wash indicated that between 69% and 77% of simvastatin was loosely surface-bound to
post-loaded particles, with no differences between simvastatin concentrations (Figure 3.4C).
Using the pre-loading technique, a significantly lower amount (p < .05), between 46% and 51% of
simvastatin, was loosely surface-bound, again with no concentration dependence (Figure 3.4A).
Pre-loaded clodronate yielded particles with 74% to 86% of drug loosely surface-bound (Figure
3.4E). Clodronate loading efficiency ranged from 91% to 97% at concentrations up to 50 mg/mL,
and dropped to 59% at 100 mg/mL (Figure 3.4F).
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Figure 3.4. Surface vs. bulk loading in microparticles: A) simvastatin post-loaded, C) simvastatin
pre-loaded, and E) clodronate pre-loaded. Loading efficiency: B) post-loaded simvastatin, D) preloaded simvastatin, and F) pre-loaded clodronate. Data are mean ± standard deviation (n=3).
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3.3.2. In vitro release
Freely mixed simvastatin was 81% released within 1 day and 95% released within 10 days,
with no difference between scaffolds prepared with or without HA (Figure 3.5A). In both cases,
there was a gradual decrease in release rate as fractional release (Mt/M∞) reached 100%. Preloaded simvastatin microparticles mixed into the system reduced the 1 day burst to 39% (p<0.05),
followed by sustained release of 1.3%/day for 30 days. The sustained release from day 1 through
day 30 was roughly linear, with no appreciable decrease in rate until completion of drug release.
Freely mixed clodronate prepared without HA exhibited a 49% burst within one day of
release, while both freely mixed and pre-loaded clodronate prepared with HA produced 32% burst
(p<0.05) (Figure 3.5B). Freely mixed clodronate without HA gradually released at a rate of
0.6%/day through day 19, while clodronate mixed with HA or pre-loaded into microparticles
released at 1.3%/day through day 19. By day 20, there was no difference in total clodronate
release between each curve. All clodronate release curves showed a distinct increase in release
rate to 3%/day at day 20 that continued through day 31, after which nearly all drug was released.
To characterize release kinetics, plots of log

𝑀𝑡
𝑀∞

vs log 𝑡 were used to calculate 𝑛 for pre-

loaded simvastatin and clodronate through the first day of release. After the first day, release
rates tended to be linear and were therefore expressed as a daily release rate. For initial release
during the burst, simvastatin and clodronate release exhibited 𝑛 = 0.47 and 𝑛 = 0.49,
respectively.
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Figure 3.5. Cumulative release profiles. A) Release of simvastatin loaded freely into the PLGA
solution with (∆) or without HA (○), or loaded into PBAE (□) (n=3). B) Release of clodronate
freely loaded into PLGA solution with (∆) or without HA (○), or loaded into PBAE microparticles
(□) (n=4). Data are mean ± standard deviation.
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3.3.3. Mass loss and degradation
Lyophilized scaffolds exhibited an initial mass loss of 50% in the first hour, followed by an
additional gradual decrease of 5% over the first day (Figure 3.6A). Mass fraction remained
unchanged at approximately 45% for 15 days, followed by a linear decrease in mass at a rate of
0.2%/day until day 50. Mass fraction did not change significantly after day 50, ranging from 25%
to 29% through day 80. Lyophilized samples collected at day 40 and beyond were primarily
powder that crumbled upon handling.
Non-destructive mass change of wet scaffolds showed an initial 12% decrease in mass
over the first day, followed by a linear increase of 1.4%/day over the next 14 days (Figure 3.6B).
At day 15, mass fraction became more variable as some samples began to decrease in mass, while
others swelled through day 30. Linear mass loss was observed from day 30 through day 55, when
the remaining mass fraction stabilized at 20% until day 80.
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Figure 3.6. Degradation of in situ forming PLGA scaffolds. A) Destructive mass loss showing dry
mass change expressed as a fraction of pre-injection mass (n=3). B) Non-destructive mass loss
showing total hydrated scaffold mass change, expressed as a fraction of pre-injection volume
(n=5). Data are mean ± standard deviation
Qualitative assessment of microCT cutplanes roughly bisecting samples revealed a
uniformly porous microstructure through day 10 (Figure 3.7). By day 15, denser regions had
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developed in the middle and at the edges of scaffolds. By day 20, large macropores were present
in the core of the scaffolds. At day 25, scaffold cores appeared more uniformly porous, and the
denser regions near the edges of scaffolds had become more porous. The dense regions appeared
to migrate towards one side of the scaffold by day 30, and by day 35, scaffolds had significantly
decreased in size, leaving behind a uniformly porous pellet. After day 35, scaffolds were too fragile
to handle, and a representative sample of residual material collected at day 40 was nonporous.
MicroCT morphometry revealed an increase in porosity from 31% through day 20 to 47% by day
30, followed by a return to 30% at day 35 (Figure 3.8A). Average pore size ranged from 40 to 100
µm, except for samples at day 25, which had average pore size of 231 µm (Figure 3.8B).
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Figure 3.7. Representative microCT cut-plane images of lyophilized scaffolds showing internal
microarchitecture throughout the degradation process. Scale bars are 1 mm.
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Figure 3.8. Morphometric parameters during degradation. A) Porosity and B) average pore size
measured by microCT evaluation of samples through 35 days.
3.4. Discussion

3.4.1. Drug loading
PBAE microparticles were successfully formed by co-grinding PBAE hydrogels with HA,
forming individual PBAE particles coated with multiple, smaller HA particles. Elemental analysis
confirmed that the smaller, spherical coating consisted of HA, and the underlying particles were
hydrogel. Simvastatin pre-loaded into PBAE hydrogels showed both higher loading efficiency and
bulk imbibition of drug, which are favorable conditions to prolong drug release relative to freely
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mixed drug. Swelling data were found to be an accurate predictor of drug loading into gels at
various concentrations, consistent with previous drug loading results with hydrogels [211]. It was
determined that processing of particles does not appreciably affect simvastatin loading efficiency
using the pre-loading technique while still providing favorable imbibition ratios of surface to bulk
drug. A decrease in loading efficiency as well as a higher percentage of simvastatin present loosely
bound to the surface of particles using a post-loading technique may be attributable to the free
HA powder used to coat the PBAE particles absorbing a percentage of drug solution, preventing
its complete penetration into the hydrogel and resulting in a majority of drug sequestered outside
the hydrogel microparticles. The high levels of surface drug seen for clodronate pre-loading may
be due to the fact that the PBAE used in these experiments swells to a significantly larger degree
in ethanol than in water (data not shown), allowing less penetration of drug into the bulk of the
gels. Additionally, clodronate was more favorably loaded into PBAEs in aqueous solutions rather
than 50% ethanol solutions because its solubility was limited. The swelling kinetics of PBAEs in the
injection mixture (30 wt% HA in 20% PLGA solution) suggest that particles swell appreciably due
to NMP exposure prior to injection, but the magnitude of swelling is negligible compared to the
amount observed in pure NMP (47% at equilibrium vs. 470% in pure NMP). This difference is due
to the presence of PLGA, which dissolves readily in NMP [146] and prevents hydrogels from fully
swelling as they would in pure NMP. Additionally, the particles may be immersed in PLGA solution
for only a matter of minutes before injection, so realistically, particles may swell by only 23% if
the system is injected 5 minutes after addition of microparticles to the PLGA solution.
3.4.2. Simvastatin and clodronate release
Simvastatin release was strongly affected by its loading state. A comparison of release
kinetics between injectable systems loaded with freely mixed simvastatin and simvastatin-loaded
PBAE microparticles indicated that burst release can be significantly reduced and duration of
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release can be significantly extended by loading simvastatin into PBAE microparticles. Because
simvastatin is soluble in NMP, freely mixed drug presumably was dissolved in NMP and the
majority of it exited into the aqueous phase during the solvent exchange process, resulting in a
large burst release. The residual 20% of simvastatin was released in a sustained manner over the
next 10 days, similar to previous work on such systems using freely mixed drug [212, 213]. PBAE
microparticles experience some swelling in the NMP-PLGA solution during the mixing stage prior
to injection, but burst is attenuated for pre-loaded PBAE microparticles. The 39% burst release
through day 1 using pre-loaded particles may be attributable to loosely surface-bound simvastatin
that was likely dissolved by NMP and released during solvent exchange, similarly to freely-mixed
simvastatin. Because simvastatin was loaded into PBAE with high efficiency, the release kinetics
are likely a combination of the swelling, degradation, and diffusion of drug through the PBAE
material as well as the PLGA phase.
Clodronate release appeared to be unaffected by loading state of the drug in PBAE
microparticles, but it was instead dependent on the presence of HA in the injection mixture. This
can be attributed to the formation of a complex between the bisphosphonate drug and
hydroxyapatite, specifically between the two phosphonate groups of clodronate and the divalent
calcium cations present in HA crystals [214]. Freely mixed clodronate without HA filler was 49%
released within 1 day, compared to 32% for both compositions with HA. Because clodronate is
insoluble in NMP, this initial burst is likely due to free clodronate suspended in the PLGA solution
being dissolved by water during solvent exchange. The increase in release rate observed around
day 20 corresponded to the maximum swelling state of scaffolds, indicating that scaffolds had
begun to appreciably degrade and more water could enter the system to promote more rapid
clodronate dissolution. Samples prepared with HA had a lower burst and higher release rate
between days 1 and 20 due to the clodronate being initially retained in the system by
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complexation, after which the drug was released diffusively from the solidified system.
Clodronate release kinetics are consistent with the classic 3-stage release profiles observed in
rapidly-precipitating systems, in which an initial burst is followed by slow diffusion, and then a
more rapid swelling- or degradation-mediated release occurs [215]. Interestingly, the slow
diffusion stage was accelerated by the addition of HA, likely because the larger amount of drug
retained in the scaffold provided a higher concentration gradient to drive diffusion.
The rapid precipitation implied by the initial burst of clodronate and simvastatin as well
as the early mass loss is indicative of rapid NMP exchange, which demonstrates the potential of
the system for rapid solidification. Fast precipitation is favorable for quick delivery of NMP for an
initial osteogenic stimulus, and rapid formation of a solid drug delivery depot may have
advantages over gradually precipitating systems with persistent gel or liquid cores for days or
weeks after injection due to NMP retention [213]. Specifically, this has implications for
intraosseous injection, where the system can completely precipitate within days while continuing
to release drug over a period of weeks to months. In systems with freely suspended or dissolved
drug, precipitation rate strongly influences burst release [137, 216], and the addition of drugloaded PBAE microparticles can allow for prolonged release and decreased burst without
prolonging precipitation of the system. The rapid precipitation may also allow filler particles, such
as hydroxyapatite, to provide mechanical support in future iterations of the system. After the
initial burst, pre-loaded simvastatin exhibited prolonged delivery over the entire 30 day period.
The lack of change in simvastatin release kinetics upon addition of 30 wt% HA was expected,
because HA should not appreciably interact with statins, which lack the phosphonate groups that
provide binding sites for the calcium in HA. The successful demonstration of sustained release of
both hydrophilic and hydrophobic small molecule drugs with reduced burst from this system
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shows promise for new applications of in situ forming PLGA systems where rapid precipitation is
required.
By fitting the power law to initial drug release, the release exponent n can be used to
classify the mechanism of drug release from the system. For simvastatin, n of 0.47 indicates
primarily Fickian diffusion based on the standard n values for a spherical scaffold of n=0.43 for
pure Fickian diffusion and n=0.85 for pure Case II transport. The slightly higher release exponent
compared to the pure Fickian value can be attributed to several factors, including the swelling of
the PBAE hydrogel microparticles and minor swelling of the surrounding PLGA matrix. Similarly, n
of 0.49 for clodronate corresponds to primarily Fickian diffusion as well. Both clodronate and
simvastatin are therefore released via diffusive mechanisms prior to their sustained release,
which follows a more linear trend. This data supports the idea that the burst was composed of a
fraction of the loaded drug dissolved or suspended in NMP, and the rapid solvent exchange was
likely responsible for the initial release. The sustained release was likely a combination of
diffusion, erosion, and swelling-based mechanisms, and the superposition of these mechanisms
produces release curves that are most simply expressed in daily release rates. Because simvastatin
is almost insoluble in water but highly soluble in NMP, the larger burst compared to clodronate is
unsurprising, as dissolved simvastatin may be transported out of the scaffold during the solvent
exchange phase. Future iterations of the system may be able to further reduce burst by reducing
access of drug to the NMP phase to limit the initial diffusive component of the system.
3.4.3. Degradation and mass loss
PLGA is a bulk-eroding material that degrades via hydrolysis of ester bonds, resulting in a
progressive decrease in molecular weight until monomeric or oligomeric species of sufficiently
low molecular weight are generated and cleared when molecular weight drops to approximately
1.5 kDa [217, 218]. The in situ forming scaffold has the additional property of a rapid precipitation
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event upon injection, and due to the high aqueous miscibility of NMP, a rapid initial dry mass loss
was observed within the first hour following injection as NMP entered the aqueous phase and the
highly hydrophobic PLGA precipitated. By 24 hours, 46% dry mass remained, corresponding to the
loss of the majority of the NMP content that composed 54 wt% of the system. The subsequent
lack of dry mass change suggests that hydrolytic degradation was unable to produce small enough
molecular weight species to be cleared into the surrounding aqueous environment until day 15.
After day 15, the linear decrease in dry mass corresponded to clearance of degradation
byproducts until all PLGA was removed from the system. The remaining 29% dry mass can be
attributed to remaining HA content that composed 30% of the original mass. For wet scaffolds,
the initial 12% decrease in wet mass throughout the first day of degradation supports the
replacement of NMP with water due to precipitation of PLGA. The 20% increase in wet mass over
the following 14 days indicates swelling of the PLGA matrix. Following this brief swelling,
individual sample behavior diverged as swelling reached a maximum between 110-120% between
days 20-30. The linear decrease in mass was delayed compared to dry samples because the small
losses in polymer degradation byproducts were offset by increased water content as the system
swelled. The lack of mass change beyond day 55 was consistent with the complete clearance of
PLGA observed in dry mass studies, and the lower mass fraction remaining (20% compared to
29%) was likely due to repeated handling of samples during nondestructive measurements
resulting in small amounts of HA being resuspended and removed with supernatant at each time
point.
Based on microCT images, it was evident that scaffold microarchitecture underwent
dramatic changes throughout the degradation process. The first indicator of change was the
development of denser regions in the core and near the edges of scaffold by day 15, which may
be attributable to the cessation of NMP release and the hydrophobicity of PLGA causing solid
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regions to condense together. At day 20, the highest pore size was observed as large, closed
macropores. This phenomenon corresponds to the scaffolds at their maximum swelling state
based on wet mass, and was accompanied by further densification of the core and edge regions.
At day 25, the core remained dense, but macropores were no longer evident, and the edges of
scaffolds were less dense and more porous, which is consistent with reports of PLGA of this
molecular weight beginning to lose mass to clearance after 3 weeks [218]. At day 30, it is possible
that enough polymer had been lost to allow mobility of HA content through the PLGA, which
settled at the bottom of scaffolds during incubation. By day 35, scaffold density and pore
distribution appeared more uniform, and scaffolds were noticeably smaller in size due to further
degradation of the highly porous regions seen at day 30.
3.4.4. Advantages of the system
In situ forming PLGA systems have been popularized due to their ease of use and unique
ability to solidify at the point of injection, forming a drug delivery depot in the tissue of interest.
However, because drug release from these systems is highly dependent on solvent exchange and
polymer chemistry [137], release of multiple agents with unique release profiles is challenging.
Additionally, low molecular weight drugs tend to exit during the solvent exchange, resulting in
high initial burst [139]. Multiple drug release platforms for small molecule drugs, therefore, tend
to be pre-formed scaffolds or injectable suspensions of micro- or nanoparticles [219-222]. The
addition of PBAE microparticles to the in situ forming PLGA system combines the ease of use of
injectable systems, the controlled release of microparticle systems, and the spatial control of solid
scaffolds. Even in a rapidly-solidifying system, PBAE microparticles are capable of prolonging
release of both hydrophilic and hydrophobic drugs over a 30 day period with significantly less
burst than traditional injectable PLGA systems using freely mixed drug.
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3.5. Conclusions
An in situ hardening, PLGA-based system offers a unique drug delivery platform due to its
injectability and space-filling properties, and the addition of drug-loaded microparticles
introduces the possibility for tunable release profiles for multiple pharmaceutical agents. In
addition to the potential for multiple release profiles, the addition of drug-loaded PBAE
microparticles enables the sustained release of water-soluble, small molecule drugs, such as
clodronate, as well as lipophilic drugs, such as simvastatin, independent of PLGA precipitation.
The biodegradability of the system makes this a favorable candidate for applications where a
secondary surgery to remove the depleted scaffold is undesirable or impossible. Release kinetics
can be multiphasic simply by loading drug freely into the PLGA solution for burst release, or into
PBAE microparticles for sustained release with reduced burst. This injectable scaffold provides the
simplicity of a targeted injection with the utility of an implantable drug delivery scaffold without
compromising desirable release kinetics.
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Chapter 4 Hydroxyapatite-Reinforced in Situ Forming PLGA Systems for Intraosseous Injection

4.1. Introduction
In situ forming poly(lactic-co-glycolic acid) (PLGA) implants have been investigated
primarily for injection into soft tissue for sustained drug delivery [195]. These systems were
conceived due to the phase separation observed when a hydrophobic polymer dissolved in a
water-miscible organic solvent is introduced to an aqueous environment, resulting in solidification
of the polymer matrix [198]. By mixing drugs into the polymer phase prior to injection, a drugloaded, solid depot can form upon injection into the body. Such systems are available in FDAapproved formulations, such as Atridox®, for delivery of doxycycline into gum tissue, and Atrigel®,
which is approved for delivery of leuprolide acetate for treatment of prostate cancer. These
systems provide prolonged drug release, with an initial burst dependent on drug and solvent
properties and a release period dependent on drug and polymer properties [139]. As such, these
injectable systems avoid the additional trauma that would be needed for implantation of large,
solid dosage forms. Furthermore, PLGA is hydrolytically degradable, so there is no secondary
surgery required to remove an implant after drug delivery is complete [218]. Because the systems
are locally injectable and space-filling, they should theoretically be able to infiltrate and conform
to complex geometries, such as a network of trabecular bone.
Most research on in situ forming PLGA systems to date has focused on modifying release
kinetics by changing solvent or polymer chemistry or concentrations [137, 200, 201]. There has
been little focus, however, on the capability of these systems to accommodate filler particles to
modify mechanical properties [223]. Recently, it was shown that hydroxyapatite (HA) and poly(βamino ester) (PBAE) additives can improve bisphosphonate and simvastatin release, respectively,
from in situ forming PLGA systems [81]. HA has also been demonstrated to improve the
osteoconductive and mechanical properties of pre-formed polymeric scaffolds for orthopedic
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applications [224-226], although to date there has been no published research on the mechanical
effects of HA additives in in situ forming PLGA scaffolds, to the authors’ knowledge.
Many orthopedic conditions result in structurally compromised bone that would benefit
from both pharmaceutical treatments and mechanical support. For example, avascular necrosis
and osteoporosis reduce both bone quality and quantity, and can ultimately lead to structural
collapse [227-229]. Trabecular bone is composed of a high-porosity, interconnected network of
bone, and the inter-trabecular space houses marrow, adipose tissue, blood vessels, and interstitial
fluid. This trabecular network is a potential target for intraosseous injection of an in situ forming
system, allowing a scaffold to form a network complementary to trabecular bone. From a
mechanical standpoint, it is beneficial to surround weakened or necrotic bone with a structurally
supportive material to prevent collapse, especially if that material can promote repair of the
compromised tissue. To this end, the previously described injectable HA-PLGA-PBAE system was
investigated for its mechanical benefits in trabecular bone.
A necessary step in designing such a system is characterizing the mechanical effects that
HA has on an in situ forming PLGA system. Scaffolds need to be considered both for their intrinsic
material properties and for their ability to augment the structural properties of trabecular bone.
Another consideration is the injectability of the system, which encompasses both force required
to extrude the mixture as well as the potential for the injection to penetrate the trabecular bone
network and solidify. The present studies investigated the mechanical and microarchitectural
properties of composite HA-PLGA-PBAE injectable scaffolds, as well their space-filling and
reinforcement effects on trabecular bone.
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4.2. Materials and Methods
4.2.1. Synthesis of PBAE microparticles
PBAE hydrogel slabs were synthesized as described previously [69, 70]. Briefly, macromer
was created by reacting diethylene glycol diacrylate with isobutylamine at 85oC for 16 hours at a
1.2:1 molar ratio. This macromer was then photopolymerized between two glass plates with 1%
w/w DMPA initiator and a 1:1 weight ratio of macromer to microparticulate hydroxyapatite (MHA)
(Sigma-Aldrich, St. Louis, MO, USA) to form a PBAE hydrogel slab. PBAE hydrogels were previously
loaded with drug for use as delivery vehicles, but were left unloaded for these experiments.
Microparticles were formed by grinding PBAE slabs and sieving until all collected particles were
250 μm or less in size.
4.2.2. NHA synthesis
Nanoparticulate HA (NHA; nGimat, Lexington, KY, USA) was produced at nGimat LLC’s
facility in Lexington, KY, using a solution combustion process called NanoSpray Combustion

SM
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This scalable process is capable of producing synthetic bone minerals, such as HA, tricalcium
phosphate (TCP), and amorphous calcium phosphate (ACP), using cost-effective precursor
materials. To produce NHA, a calcium carboxylate precursor and an alkyl phosphate precursor of
appropriate proportions were dissolved in an organic solvent system, the solution was converted
to an ultrafine spray (referred to as a NanoSpray) using a device called a Nanomiser®, and the
spray was combusted under a controlled atmosphere. The average particle size for the NHA was
<200 nm, as estimated by BET. X-ray diffraction confirmed the presence of the HA phase
(Ca5(OH)(PO4)3), and X-ray fluorescence spectroscopy showed that the Ca:P ratio was close to 5:3.
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4.2.3. Formation of cylindrical scaffolds
PLGA (50:50 L:G, acid terminated, inherent viscosity 0.55-0.75 dL/g ) was obtained from
DURECT, Inc. (Birmingham, AL, USA). All experiments used a polymer solution of 30% w/w PLGA
in NMP (Sigma-Aldrich, St. Louis, MO, USA). PBAE microparticles and MHA or NHA were mixed
homogeneously into the polymer solution using a spatula. The scaffold mixture was loaded into a
syringe and injected through a 16 gauge needle into a cylindrical agarose mold, where the system
was allowed to solidify in phosphate-buffered saline (PBS). Scaffolds contained different
concentrations of MHA or NHA, ranging from 0% to 50% w/w. All scaffolds contained 5% w/w
PBAE microparticles to mimic prior drug release study conditions, unless otherwise indicated. PBS
was replaced daily to prevent accumulation of NMP or low molecular weight species that were
cleared from the scaffolds.
4.2.4. Mechanical properties of cylindrical scaffolds
All compression tests were performed using a Bose ELF 3300 mechanical testing
instrument. Modulus was calculated as the slope of the initial linear region of the stress-strain
curve (approximately the first 5-10% strain). Yield stress was determined as the stress at which
the stress-strain curve became nonlinear. To first identify any strain rate-dependence of
mechanical properties, scaffolds prepared with increasing MHA content were tested in
unconstrained compression to 50% strain at displacement rates of 0.006, 0.06, and 0.6 mm/s
(strain rates of 0.001, 0.01, and 0.01 s-1, respectively). The contribution of PBAE microparticles to
mechanical properties was quantified by increasing PBAE content from 1% to 15% w/w in
scaffolds prepared with 30% NHA.
To determine the effects of NHA versus MHA on scaffold properties, a comparison of
mechanical properties for scaffolds containing different amounts of MHA and NHA was
performed at a displacement rate of 1 mm/min (0.0167 mm/s, or a strain rate of 0.0028 s -1) to
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50% strain. Total HA content ranged from 0 to 50% in intervals of 10%. Scaffolds were prepared
with either pure MHA, pure NHA, or different ratios of the two.
4.2.5. Injectability
To quantify injectability, scaffold mixtures containing 30% w/w NHA and 5, 10, or 15%
w/w PBAE microparticles were loaded into a 3 mL syringe affixed with a 1.5 inch, 16 gauge needle.
The loaded syringe was suspended by its flanges in a 15 mL centrifuge tube to collect the injected
mixture, with the end of the tube in contact with the load cell and the plunger of the syringe in
contact with the axial mover. The plunger was subjected to a series of sustained loads to simulate
injection force, and the resulting displacement of the plunger was recorded. Injectability was
quantified by plotting the time to inject 0.5 mL as a function of the injection force. Rational limits
of 60 second injection time and 50 N injection force were set as the limits of injectability based
on consultation with an orthopedic surgeon (T.A.M.).
4.2.6. Microarchitecture
Effects of HA on microarchitecture were analyzed by preparing scaffolds with increasing
NHA and MHA content, as well as a variety of NHA/MHA mixtures totaling 30% HA, lyophilizing
these scaffolds after they had solidified in PBS for 3 days, and then scanning them with a SCANCO
MicroCT 40 (SCANCO Medical AG, Switzerland) at 55 kV and 145 mA and 6 μm voxel size.
Microarchitecture was quantified by porosity and material density. Scanning electron microscopy
(SEM) was used to visualize micro- and nanoarchitecture of scaffolds containing 30% w/w NHA.
Samples were freeze-fractured, coated with gold-palladium alloy, and imaged with a Hitachi S4300 scanning electron microscope at 3 kV accelerating voltage.
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4.2.7. Ex vivo scaffold injections
Humeral heads were harvested from 10 week old male piglets euthanized in a separate
study, and were kept frozen until use, without chemical fixation or removal of marrow. Using a
16-gauge, 2.5-inch bone biopsy needle inserted through the growth plate into the proximal
humeral epiphysis, two humeral heads each received 3 mL ex vivo injections of 30% NHA / 5%
PBAE scaffolds. Two humeral heads were used as untreated controls. All humeral heads were
scanned using microCT prior to injection, immersed in PBS for 5 days to allow scaffolds to fully
solidify, and then scanned again to quantify scaffold infiltration. After 5 days in PBS, a 3 mm
diameter cylindrical punch was used to remove tissue samples in the mediolateral direction, with
the punch approaching through the articular cartilage and penetrating through the growth plate,
for a total of 7 samples each for treatment and control groups. These cylindrical samples were
trimmed to 6 mm in length, using only trabecular bone tissue between the growth plate and the
articular cartilage. All samples were stored in PBS and tested the same day in unconstrained
compression at a rate of 1 mm/min.
4.3. Results
4.3.1. Strain rate and MHA content
Scaffolds prepared with different MHA contents were compressed at strain rates
spanning three orders of magnitude. At strain rates of 0.001, 0.01, and 0.1 s-1 (corresponding to
displacement rates of 0.006, 0.06, and 0.6 mm/s), modulus increased with MHA content (Figure
4.1A). The highest modulus increased from 64 to 82 to 96 MPa for each respective strain rate, and
overall, moduli ranged from 9 to 96 MPa. The lowest recorded modulus for any scaffold containing
HA was 29 MPa (10% MHA, 0.001 s-1), while scaffolds without any HA ranged from 9 to 30 MPa,
increasing with strain rate. At 0.001 s-1, significant increases in modulus occurred between 0-10%
(p<0.01) and 30-50% MHA (p<0.01). At 0.01 s-1, significant increases occurred between 0-20%
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(p<0.05) and 20-50% MHA (p<0.0001). At the highest strain rate of 0.1 s-1, modulus increased
between 0-10% (p<0.01), 10-30% (p<0.001), and 30-40% MHA (p<0.001). For equivalent scaffold
formulations, average modulus increased with increasing strain rate in every case, and this trend
was significant at 40% MHA between 0.01 and 0.1 s-1 (p<0.0001) and at 50% w/w MHA between
0.001 and 0.01 s-1 (p<0.05).
Yield stress followed a similar trend to modulus, however the differences between
scaffold formulations and between strain rates were less pronounced (Figure 4.1B). Yield stresses
ranged from 1.1 to 7 MPa, and the highest yield stresses at the three strain rates of 0.001, 0.01,
and 0.1 s-1 were 4.4, 5, and 7 MPa, respectively. Addition of 10% MHA to scaffolds led to a
threefold increase in yield stress at a strain rate of 0.001 s-1 (from 1.1 to 3.3 MPa) and a twofold
increase in yield stress at 0.01 s-1 (from 2 to 4.2 MPa), while 10% MHA scaffolds experienced only
a 13% increase (from 4.5 to 5.1 MPa) at a strain rate of 0.1 s-1. At 0.001 s-1, significant increases
in yield stress occurred between 0-10% (p<0.0001) and 40-50% MHA (p<0.01). At 0.01 s-1, yield
stress significantly increased at 0-10% (p<0.0001) and 10-30% MHA (p<0.01). At the highest strain
rate of 0.1 s-1, yield stress increased from 0-20% (p<0.05) and 20-50% MHA (p<0.05). Similar to
modulus, average yield stress for equivalent scaffold formulations increased at every strain rate.
Increasing strain rate from 0.001 to 0.01 s-1 led to an increase in yield stress for 20% (p<0.001),
30% (p<0.01), and 40% MHA scaffolds (p<0.001). Further increasing strain rate from 0.01 to 0.1 s1

resulted in significantly increased yield stress for 0% (p<0.0001), 30% (p<0.01), 40% (p<0.01),

and 50% MHA scaffolds (p<0.0001).
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Figure 4.1. Mechanical properties of cylindrical scaffolds prepared with different MHA content
and tested at multiple strain rates. A) Compressive modulus. B) Yield stress. Data are grouped by
displacement rate and ordered by increasing MHA content. Shared letters denote statistical
similarity, and columns without a single shared letter are significantly different. Data are mean ±
standard deviation (n=3).
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4.3.2. PBAE content
Scaffolds prepared with 30 w/w% NHA and different PBAE microparticle contents were
compressed at 1 mm/min (0.0028 s-1). PBAE microparticle content did not significantly affect 30%
NHA scaffold mechanical properties for PBAE content ranging from 1 to 10 w/w %. Moduli ranging
from 96-120 MPa (Figure 4.2A) and yield stresses from 4.3-4.9 MPa (Figure 4.2B) were recorded
in these PBAE content ranges, with the highest modulus occurring at 10% PBAE and the highest
yield stress occurring at 1% PBAE. Increasing PBAE content from 10 to 15% led to a significant
decrease in modulus from 120 to 84 MPa (p<0.05). Average yield stress of 15% PBAE scaffolds was
3.6 MPa, significantly lower than 1% PBAE scaffolds (p<0.05), which had an average yield stress of
4.9 MPa. Samples became more viscous and difficult to inject into molds as PBAE content was
increased. Beyond 15% PBAE, the mixture could still be injected, but the scaffold began
precipitating before it could flow and fill the cylindrical mold, resulting in inconsistent morphology
and unreliable mechanical properties.
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Figure 4.2. Mechanical properties of 30 w/w % NHA scaffolds prepared with increasing PBAE
microparticle content. A) Compressive modulus. B) Yield stress. Shared letters denote statistical
similarity, and columns without a single shared letter are significantly different. Data are mean ±
standard deviation (n=3).
4.3.3. Ratio of MHA to NHA
Scaffolds prepared with different amounts of MHA and NHA were compressed at 1
mm/min (0.0028 s-1). All scaffolds generally increased in modulus up to 30% w/w total HA content
(Figure 4.3A). In scaffolds prepared with only MHA, a linear increase in modulus from 33 to 68
MPa was observed from 10% through 30% MHA, although no significant difference was observed
between groups. Modulus was significantly different between 10% and 50% MHA scaffolds
(p<0.05). Scaffolds prepared with only NHA exhibited a large and significant increase in modulus,
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from 53 to 141 MPa, between 20% and 30% NHA (p<0.0001). Scaffolds prepared with equal
amounts of NHA and MHA possessed moduli similar to 30% NHA scaffolds, with 15:15, 20:20, and
25:25 NHA:MHA scaffolds all exhibiting moduli between 128 and 151 MPa. Other scaffolds with
similarly high moduli included mixed NHA and MHA scaffolds with total HA concentrations of 50%
(10:40, 20:30, and 30:20 NHA:MHA). Notably, 20:10 scaffolds exhibited significantly lower
modulus than 15:15 and 30:0 NHA:MHA scaffolds (p<0.0001). Scaffolds with 40% and 50% total
had the highest modulus at a 1:1 NHA:MHA ratio, which decreased when the NHA:MHA ratio was
changed in either direction.
Yield stress followed trends similar to modulus, however the magnitude of these
differences was lower (Figure 4.3B). For example, out of all scaffolds prepared with 30% total HA,
only 30:0 and 10:20 NHA:MHA samples were significantly different (p<0.01). Scaffolds made with
40% pure MHA or 40% pure NHA had significantly lower yield stresses than scaffolds prepared
with a mixture of NHA and MHA (p<0.01). At 50% total HA, scaffolds with 30% or higher NHA
content possessed lower yield stresses than scaffolds composed of 25:25, 20:30, or 10:40
NHA:MHA (p<0.01).
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Figure 4.3. Mechanical properties of scaffolds prepared with different MHA:NHA ratios, grouped
by increasing total HA content (w/w %) and subsequently ordered by increasing MHA content
(w/w %). A) Compressive modulus. B) Yield stress. Shared letters denote statistical similarity, and
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columns without a single shared letter are significantly different. Data are mean ± standard
deviation (n=3).
4.3.4. Injectability
Injectable scaffold mixtures containing 5, 10, or 15 w/w% PBAE microparticle content
were injected through a 16 gauge, 1.5 inch needle with a series of increasing injection forces. For
each injection, the displacement of the plunger initially increased rapidly due to compression of
the rubber plunger, the scaffold mixture, and any air bubbles, before reaching a period of linear
displacement where flow rate was constant, followed by a relaxation period as force was removed
(Figure 4.4A). The linear portion of the displacement curve was used to calculate displacement
rate of the syringe plunger, and the internal diameter of the syringe barrel was used to calculate
volumetric flow rate. The time required to inject 0.5 mL of each mixture increased with increasing
PBAE content, and it decreased with increasing injection force (Figure 4.4B). Scaffolds were
considered injectable if a 0.5 mL injection could be performed in 60 seconds or less, which is
indicated by the horizontal dashed line in Figure 4B. The 5% PBAE scaffolds were injectable for
injection forces greater than 16 N, 10% PBAE scaffolds became injectable at 40 N, and 15% PBAE
scaffolds became injectable at 75 N. The vertical dotted line at 50 N in Figure 4B indicates the limit
for a reasonable injection force, beyond which sustained forces may be uncomfortable or cause
fatigue for the surgeon performing the procedure. For each scaffold composition, a logarithmic
transformation of both injection force and injection time resulted in the best fit.
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Figure 4.4. Injectability of 30% NHA scaffold mixtures prepared with varying PBAE microparticle
content. A) Representative graph of collected force (green curve, left axis) and displacement (blue
curve, right axis) data, with the highlighted linear portion of the displacement used to calculate
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volumetric flow rate. B) Time required to inject 0.5 mL from a 16 gauge needle for various injection
forces and PBAE microparticle contents. The dotted lines indicate reasonable limits for injection
time for 0.5 mL (60 sec) and injection force (50 N). Data are mean ± standard deviation (n=3).
4.3.5. Microarchitecture
Visualizing the microarchitecture of scaffolds prepared with 30% w/w NHA and 5% w/w
PBAE microparticles revealed two distinct levels of porosity, with NHA and PBAE particles trapped
within the solid PLGA matrix. Macroscopic pores on the order of 100 μm in diameter were
scattered throughout the scaffold (Figure 4.5A), and the solid PLGA matrix was primarily
composed of a microporous, honeycomb-like structure with pore sizes on the order of 10 μm
(Figure 4.5B). Elongated pores were observed at the scaffold surface (Figure 4.5C). HA
nanoparticles, with spherical morphology and diameters on the order of 50 nm, were present in
the PLGA walls of the micropores (Figure 4.5D). These particles were densely packed in 30% w/w
NHA scaffolds.
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Figure 4.5. SEM images of 30% w/w NHA scaffold microarchitecture, showing A) macropores on
the order of 100 μm (white arrows), B) microporous PLGA substructure, C) elongated pores
perpendicular to the surface (dotted arrows), and D) NHA nanoparticles embedded in the PLGA
matrix (black arrows).
MicroCT analysis allowed for quantification of microarchitectural parameters such as
porosity and material density. Porosity generally decreased with increasing total HA content, and
this trend was most pronounced in samples prepared with only MHA, which possessed porosities
ranging from 2.4 to 48.1%, while samples prepared with only NHA had a porosity range of 13 to
22.5% (Figure 4.6A). MHA-only samples experienced a significant decrease in porosity from 1020% (p<0.001) and 30-40% (p<0.05), and NHA-only samples had a significant decrease in porosity
from 10-30% (p<0.05). Samples with 30% total HA prepared with different mixtures of MHA and
NHA did not exhibit significantly different porosity from each other. At equivalent weight
percentages, samples prepared with pure NHA had significantly lower porosity than those
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prepared with MHA at 10% (p<0.0001), 20% (p<0.001), and 30% (p<0.05), while porosity between
the two groups was not different at 40% and 50% w/w.
Material density increased with total HA content, and scaffolds prepared with NHA
experienced a larger increase in density at each 10% increment of HA content (Figure 4.6B). MHA
scaffolds exhibited significantly higher density than NHA scaffolds at 10% (p<0.0001) and 20%
(p<0.01), but due to the smaller rate of increase, they exhibited lower density than NHA scaffolds
at 30%, 40%, and 50% w/w (p<0.0001). The 30% HA scaffolds prepared with a mixture of NHA and
MHA had lower density at 10:20 NHA:MHA formulations than scaffolds prepared with 15:15 and
20:10 NHA:MHA (p<0.0001).
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Figure 4.6. MicroCT analysis of scaffolds prepared with varying NHA and MHA content, showing
A) porosity and B) material density of cylindrical samples. Data are grouped by total HA content,
and ordered by increasing NHA content. Shared letters denote statistical similarity, and columns
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without a single shared letter are significantly different. Data are mean ±- standard deviation
(n=3).
4.3.6. Ex vivo scaffold injections
During the injection of scaffolds into the humeral heads, fluid was observed leaking out
of bone near the growth plate, indicating that the scaffold was displacing marrow and filling the
intertrabecular space. After the 3 mL injection into two humeral heads, there was an average
reduction in free volume of 2.8 mL, corresponding to a 58% filling of the intertrabecular volume
(data not shown). A comparison of cutplanes from a 3D reconstruction of the humeral heads
showed scaffold material distributed throughout the bone volume, with small (sub-millimeter)
regions of that were unfilled (Figure 4.7A). During removal of the cylindrical cores from injected
bones, it was observed that scaffold material was constrained by the articular cartilage and
growth plate (Figure 4.7B). Cylindrical samples of injected bone possessed a mean compressive
modulus of 180 MPa, compared to 81 MPa for controls (p<0.001) (Figure 4.7C). Yield stress was
also significantly higher for injected bone, with a yield stress of 5.9 MPa for injected samples
compared to 3.5 MPa for controls (p<0.01) (Figure 4.7D).
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Figure 4.7. Microstructural and mechanical properties of trabecular bone samples from porcine
humeral heads with or without injection of 30% NHA / 5% PBAE scaffolds. A) MicroCT cutplane of
humeral head prior to injection (left) and post-injection (right). B) Cylindrical bone sample
containing solidified scaffold. C) Compressive modulus. D) Yield stress. Data are mean ±- standard
deviation (n=7). *Significantly different from Control (p<0.001). **Significantly different from
Control (p<0.01). Scale bar is 5 mm.
4.4. Discussion
4.4.1. Mechanical properties
The general effects of HA additives on in situ forming PLGA scaffolds were consistent with
existing research on preformed, implantable scaffolds [224, 230-232], with HA additives providing
mechanical reinforcement, as evidenced by both compressive modulus and yield stress. As HA
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content was increased beyond a certain point (generally around 30% w/w, depending on the
specific MHA and NHA content), mechanical properties either plateaued, in the case of MHA, or
decreased, in the case of NHA. This effect can be attributed to the total surface area of HA relative
to the volume of PLGA, which results in maximal scaffold mechanical properties when sufficient
PLGA is present to bind HA together tightly without excess HA or PLGA. SEM images of the 30%
NHA scaffolds showed dense packing of NHA nanoparticles embedded in the PLGA phase, which
may explain why further increasing NHA content was not beneficial since particles were already
in close proximity at this loading. MHA scaffolds were mechanically inferior to NHA at equivalent
concentrations, likely due to the lower surface area to volume ratio of MHA, which allowed fewer
PLGA:HA and HA:HA interfaces to form, and thus led to a more loosely packed HA microstructure.
Additionally, there may exist a critical threshold for particle size, below which significant
mechanical benefits occur in a composite [233]. Scaffolds with a higher NHA and MHA packing
capacity could potentially be created by increasing PLGA concentration in the PLGA/NMP solution
[232], however, this would also increase the viscosity of the injectable mixture [234].
Interestingly, scaffolds prepared with equal amounts of NHA and MHA tended to possess
comparable mechanical properties to scaffolds prepared with pure NHA or pure MHA. This
similarity may be due to the tight packing of NHA in the spaces between MHA particles, resulting
in scaffolds that are effectively identical to tightly packed NHA when compressed. Ultimately, the
similarity between pure NHA and equally mixed NHA/MHA scaffolds is probably the result of two
factors: 1) HA should be present at sufficient concentrations so that load is primarily being
transmitted between tightly packed HA particles, and 2) enough PLGA should be present so that
it can bind all the HA particles together. For a system intended for intraosseous injection,
however, 30% NHA provides the highest mechanical properties at the lowest total HA
concentration, and was therefore the most appealing formulation in terms of injectability.
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Native trabecular bone in human femoral heads has a wide range of mechanical
properties, with compressive moduli ranging from 100-600 MPa and yield strength ranging from
1-9 MPa [227, 235]. For conditions that may be candidates for an injectable, intraosseous
treatment, these values may be reduced by 24% (yield stress) and 20% (modulus) in osteoporotic
patients [227], or 50% (yield stress) and 72% (modulus) in osteonecrosis patients [235]. Scaffolds
with material properties similar to trabecular bone can aid load-bearing while the drug delivery
component of the scaffold exerts its effect [236]. The average modulus of scaffolds prepared with
30% NHA was 141 MPa, and the average yield stress was 6.2 MPa, which are both within the range
of trabecular bone. Although in situ forming PLGA systems have not been extensively investigated
for their mechanical properties, the strength of these scaffolds is 10-fold higher than a similar
system containing 33% α-tricalcium phosphate and PLGA of a lower molecular weight [223].
Furthermore, the yield stress was on the higher end of healthy trabecular bone, so even if
scaffolds are slightly less stiff than the native bone tissue, they can withstand similar stresses to
healthy bone before beginning to collapse. It is important to consider these scaffolds as a means
for temporary augmentation that can acutely preserve bone while treatment occurs, not as a
replacement for healthy bone tissue. For this purpose, the material properties of the 30% NHA
system are sufficient.
4.4.2. Injectability
Injectability is a unique concern for in situ forming scaffolds, because both HA and PBAE
particle additives increase viscosity. Becaue prior injectable PLGA systems were not intended for
mechanical support, and drug is usually mixed freely into the polymer solution, viscosity has not
been a limiting factor when designing these systems. However, injectable bone cements and
fillers have encountered issues with injectability because they are composed of a liquid phase
containing high concentrations of suspended particles [237, 238]. For example, decreasing the
75

liquid to powder ratio increases the required injection force and decreases the extruded fraction
[237, 239], which is roughly analogous to increasing HA content in an injectable PLGA system.
Various additives have been investigated to decrease the required injection force [240].
Injectability will likely be a persistent, nontrivial issue for in situ forming PLGA systems containing
mechanical filler. Setting NHA content to a constant 30% and varying PBAE microparticle content
revealed that there is a clear limit on PBAE microparticle content (and, therefore, drug loading)
beyond which the system cannot be injected without exceeding limits of injection force or
injection time. Longer-duration injections may be complicated by the precipitation of PLGA into a
solid [241], leading to increased backpressure and a loss of injectability, while injections requiring
large sustained force may be uncomfortable for the surgeon performing the procedure. The
injection force limit may be circumvented by the use of an injection gun, which would improve
injection time and greatly increase the injection force limit.
4.4.3. Ex vivo injections
The space-filling and mechanical reinforcement potential of an injectable system is likely
to differ in situ from simulated tests, due to the presence of a constrained geometry filled with
marrow and bordered by anatomical features such as articular cartilage, cortical bone, and the
growth plate. The incomplete filling of free volume by the scaffold suggests that the material
establishes flow channels of low resistance, resulting in small pockets of unfilled bone. MicroCT
images and cylindrical tissue samples, however, show that these unfilled regions are distributed
throughout the bony network, and the scaffold was capable of filling the bone tissue in all
directions. Furthermore, injected bone tissue was significantly stronger and stiffer than native
tissue, suggesting that the 58% filling that was achieved is sufficient to greatly improve mechanical
properties of trabecular bone.
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4.4.4. Advantages of the system
An in situ forming HA-PLGA-PBAE implant offers several advantages over traditional
orthopedic injectables, such as poly(methyl methacrylate) (PMMA) bone cement. The heat of free
radical polymerization of PMMA in situ can lead to protein denaturation and tissue necrosis [242],
whereas in situ forming PLGA scaffolds are formed via solvent exchange at ambient temperature.
PMMA is not biodegradable, while PLGA degrades hydrolytically over a time period dependent on
its chemical properties [218]. Biodegradation is important for a drug delivery scaffold embedded
in a trabecular network, where removal surgery is impossible and a permanent implant is not
ideal. Finally, the mechanical properties of PMMA are a better match for cortical bone than a
trabecular bone network, while PLGA is a less stiff material that may be appropriately augmented
to match trabecular bone via addition of HA filler [236, 243]. An implant that acutely reinforces
compromised bone, controls drug release, and gradually degrades to allow regeneration of native
tissue can provide a comprehensive treatment in a single injection.
4.5. Conclusions
The present study demonstrated the feasibility of an injectable PLGA scaffold containing
PBAE and HA particles as a mechanically supportive, in situ forming scaffold. Injectable scaffold
mixtures are capable of being injected through a standard bone biopsy needle, infiltrating
trabecular bone, then solidifying to produce scaffolds with mechanical properties comparable to
those of trabecular bone. This injectable scaffold offers a promising treatment platform for
ailments requiring both drug delivery and mechanical reinforcement of trabecular bone, and it
has the advantage of being easily injectable and fully resorbable. This particular system was
optimized to accommodate NHA mechanical filler and PBAE microparticles for drug delivery, with
the goal of an intraosseous injection into the femoral head. In situ forming PLGA systems have
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traditionally been viewed purely as drug delivery devices, but this study clearly demonstrates the
potential for a mechanical component to these systems as well.
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Chapter 5 Poly(β-amino ester) hydrogel microparticles to improve in situ forming delivery
systems for periodontitis

5.1. Introduction
Periodontitis is a complex oral infection, in which bacteria colonize below the gum line,
leading to the destruction of multiple tissues, including the gingiva, alveolar bone, and
periodontal ligament [151]. Beyond the progressive deterioration of oral health leading to tooth
loss, periodontitis has also been implicated in systemic conditions such as cardiovascular and
cerebrovascular disease, and diabetes [153, 154]. Traditionally, periodontitis is treated with
mechanical removal of bacteria from tissue surfaces in a process called scaling, followed by
smoothing of the tooth surface, called root planing [157]. In many cases, scaling and root
planing are accompanied by local or systemic delivery of antibiotics to treat difficult infections
and to prevent recurrence [158]. However, systemic antibiotics can lead to adverse side effects
due to the relatively high dosage required to provide sufficient concentration in oral tissues, and
simple local delivery, such as rinses, needs to be repeated frequently to maintain appropriate
antibiotic concentrations. Therefore, local delivery systems have been developed to maintain
antibiotic dosages within the periodontal pocket [244-246]. In advanced cases of periodontitis,
significant alveolar bone loss occurs, and augmentation procedures involving implanted grafts or
scaffolds may be used to promote bone regrowth after the infection has been cleared [151,
247].
A single, injectable therapy, containing both antibiotic and osteogenic components in a
biodegradable scaffold, can potentially provide an all-encompassing, minimally invasive
treatment for this condition. The commercially available Atridox® system is an injectable
formulation of poly(lactic-co-glycolic acid) (PLGA) containing doxycycline, an antibiotic, and has
been shown to maintain local doxycycline concentrations above the minimum inhibitory
79

concentration for over 1 week. Recently, a similar system containing particulate additives for
orthopedic applications was investigated for delivery of simvastatin, which has osteogenic and
anti-inflammatory properties [81].
Historically, little focus has been placed on these in situ forming implants (ISIs) for their
potential as scaffolds for new tissue growth. This is due to the dense, solid microstructure,
which is not conducive to cellular infiltration [248], as well as the tendency of these implants to
loosen within the periodontal pocket, which can also lead to fragments of polymer breaking off
and dislodging.[246] Incorporation of degradable or soluble porogen particles into delivery
systems improves the microstructure of these scaffolds [248], and incorporation of bioadhesive
polymers and plasticizers was shown to improve adhesive properties [249]. The mechanical
properties of ISIs, as well as the physical changes (i.e., swelling and microarchitectural changes),
are important for periodontal applications, because the periodontal pocket presents a
constrained geometry that is subject to cyclical stresses from chewing, and compared to the
gingiva, PLGA is a stiff material prone to plastic deformation. Conceivably, a highly porous
material that swells to fill the pocket and releases both antibiotic and osteogenic stimuli may be
beneficial for future consideration as a scaffold for tissue regeneration. Biodegradable poly(βamino ester) (PBAE) hydrogel microparticles have been used previously to modulate both drug
release and microarchitecture of PLGA ISIs designed for orthopedic applications [81]. A first step
towards testing adapting PBAE-loaded PLGA ISIs for periodontitis is to quantify the drug release
and material changes due to these additives. Therefore, the aim of this study was to
demonstrate acute antibiotic delivery accompanied by co-delivery of an antibiotic and an
osteogenic agent from PBAE-containing PLGA ISIs, and to quantify the effects of these PBAE
additives on swelling, degradation, microarchitecture, and mechanical properties.
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5.2. Materials and Methods
5.2.1. Materials
Diethylene glycol diacrylate and poly(ethylene glycol) 400 diacrylate (PEG400DA) were
bought from Polysciences, Inc. (Warrington, PA). 2,2-Dimethoxy-2-phenylacetophenone
(DMPA), high molecular weight PLGA (HMW PLGA; 50:50 lactide:glycolide, 0.55-0.75 dL/g in
hexafluoroisopropanol, carboxylate-terminated), low molecular weight PLGA (LMW PLGA; 50:50
lactide:glycolide, 0.15-0.25 dL/g in hexafluoroisopropanol, carboxylate terminated) were
purchased from DURECT (Birmingham, AL). N-methyl-2-pyrrolidone (NMP), gelatin (from porcine
skin, type A), glutaraldehyde (25%, grade I), agarose, trifluoroacetic acid (TFA), doxycycline
hyclate, and glycine were obtained from Sigma Aldrich (St. Louis, MO). Simvastatin was from
Haorui Pharma-Chem (Edison, NJ).
5.2.2. PBAE hydrogel preparation
PBAE macromer was created by reacting a diacrylate with isobutylamine at 85°C for 48
hours. Macromers were named according to the classification system from Anderson et al., in
which the letter corresponds to a specific diacrylate and the number corresponds to a specific
amine [69]. Thus, macromer made by reacting PEG400DA with isobutylamine for 48 hours was
termed H6. A macromer containing a 2:1 molar ratio of diethylene glycol diacrylate:PEG400DA
was also created, and will subsequently be referred to as AH6.
PBAE hydrogels were formed by adding 0.1% w/w DMPA, dissolved in ethanol, to the
macromer, pipetting this mixture between two parallel glass plates, and exposing the mixture to
a 365 nm UV flood source for 5 minutes to crosslink the macromer. The resulting hydrogels were
washed overnight in ethanol to remove residual DMPA and unreacted monomers, and were
stored in a desiccator until use.
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PBAE microparticles were made by swelling PBAE hydrogels in ethanol for 1 hour and
then grinding them with a mortar and pestle. The slurry was passed through a 250 μm sieve
using an ethanol wash, and any larger particles were re-ground until 100% of the hydrogel was
sieved. The microparticle slurry was lyophilized, and the resulting microparticles were stored in
a desiccator.
5.2.3. Injectable mixture formulations
A PLGA solution was formed by dissolving 30% or 40% w/w of either HMW or LMW
PLGA in NMP overnight. PBAE microparticles (H6, AH6, or a mixture of the two) were added to
the PLGA solution at 10% w/w and stirred until the mixture was homogeneous. 2% w/w
simvastatin or doxycycline (or 2% w/w each for co-delivery) were added to the PLGA-PBAE-NMP
suspension and mixed thoroughly. Alternatively, doxycycline was pre-loaded into AH6
microparticles by swelling the microparticles with a 3 mg/mL doxycycline solution in acetone at
a ratio of 100 mg AH6 to 500 µL of solution. These swollen particles were lyophilized for 24
hours, resulting in doxycycline pre-loaded into AH6 microparticles. Pre-loaded AH6
microparticles at 10% w/w in PLGA solutions were then used in drug release studies. HMW
formulations containing simvastatin were tested first, and the most promising mixtures were
used in subsequent tests with doxycycline and/or LMW PLGA. Table 5.1 contains a list of all
scaffold formulations that were examined for these drug release studies.
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Table 5.1. Scaffold formulations investigated for drug release. S = simvastatin. D = doxycycline.
HMW = high molecular weight PLGA. LMW = low molecular weight PLGA. (Pre) indicates drug
was pre-loaded into PBAE microparticles. “+” indicates co-delivery from the same scaffold.
Scaffold Name
HMW-AH
HMW-H
HMW-H/AH
HMW-Control
LMW-AH
LMW-Control
40LMW-AH
40LMW-Control

PLGA
HMW
HMW
HMW
HMW
LMW
LMW
LMW
LMW

PLGA %
30
30
30
30
30
30
40
40

PBAE
AH6
H6
AH6+H6
None
AH6
None
AH6
None

Drugs
S / D / S+D / D(Pre)
S
S
S/D
S / D / S+D
S / D / S+D
S / D / S+D / D(Pre)
S / D / S+D / D(Pre)

5.2.4. Microstructure and mass change
To observe changes in ISI mass and microstructure, the following drug-free formulations
were prepared: HMW-AH, HMW-H, HMW-H/AH, HMW-Control, LMW-AH, and LMW-Control
(Table 5.1). In a 96-well plate, approximately 10 mg of injectable scaffold mixture was injected
dropwise from an 18-gauge needle into 300 µL PBS. The syringe was weighed after each
injection to calculate the mass of each scaffold. PBS was replaced daily to prevent buildup of
degradation byproducts. At each time point, 3 scaffolds from each group were removed, dabbed
dry, and weighed to measure the wet mass. For HMW scaffolds, scaffolds were collected at 1
day and 5 days following the injection, and for every 5 days thereafter. For LMW scaffolds,
scaffolds were collected at 1 day, 2 days, and every other day thereafter. All collected ISIs were
lyophilized for 24 hours and weighed again to determine dry mass. HMW scaffolds were then
scanned using a SCANCO MicroCT 40 (SCANCO Medical AG, Switzerland) with X-ray parameters
of 55 kV and 145 mA, and a 6 μm voxel size. A built-in bone trabecular morphometry analysis
tool was used to create 3-D reconstructions, and measurements of porosity, mean pore size,
and material density were conducted. To quantify accessible volume and surface area,
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simulated mercury intrusion porosimetry was run on the 3-D reconstructions using an included
script. At select time points, samples were freeze-fractured, and a Hitachi S-4300 scanning
electron microscope (SEM) at 4 kV accelerating voltage was used to visualize the
microarchitecture of scaffolds.
5.2.5. Mechanical tests
All mechanical tests were performed with a Bose ELF 3300 system. Gelatin slabs (20%)
measuring 8 mm thick was prepared, and were crosslinked by immersing overnight in 5 mM
glutaraldehyde. The aldehyde groups were quenched by immersing crosslinked gelatin slabs in a
50 mM glycine solution for 2 hours and washing serially in deionized water. Cylindrical samples
(4 mm in diameter) were punched out of the slabs, and their mechanical properties were
characterized by compressing these cylindrical samples to 10% strain at a frequency of 1 Hz for
30 seconds to mimic chewing conditions [250]. The slabs containing cylindrical holes were used
as molds to inject HMW-Control and HMW-AH scaffolds measuring 8 mm length by 4 mm
diameter. After injection, the molds were capped with 2% agarose slabs, clamped shut lightly to
prevent extrusion of material due to swelling, and immersed in PBS. After 3, 6, 9, 12, or 15 days,
the solidified samples within the molds were subjected to a displacement rate of 0.5 mm/sec.
The interfacial shear strength required for push-out was calculated by dividing the maximum
push-out force by the scaffold surface area in contact with the mold. Cylindrical scaffolds that
had been pushed out of their molds were tested for their compressive properties under 1%
strain triangular waves applied at a frequency of 1 Hz for 60 seconds. The initial modulus was
determined from the first compression cycle, and the equilibrium modulus was measured during
the final cycle. Resilience was calculated by integrating the linear region of the stress-strain
curve.
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5.2.6. Drug release
Approximately 100 mg of each mixture (Table 5.1) was injected dropwise into 1 mL PBS
(n=3), where the PLGA rapidly solidified into droplet-shaped scaffolds. At each time point,
supernatant was entirely removed, stored in a refrigerator, and replaced with fresh PBS. A
Hitachi Primaide HPLC system with a C18 column was run isocractically at 1 mL/min with a
mobile phase composed of 70% acetonitrile / 30% water + 0.1% TFA to detect simvastatin at
240 nm. Collected supernatant was mixed with ethanol at a 2:1 supernatant:ethanol ratio to
dissolve any precipitated simvastatin prior to HPLC analysis. Doxycycline was assayed using a
mobile phase composed of 30% acetonitrile / 70% water + 0.1% TFA running at 1 mL/min and
with detection at 350 nm.
5.3. Results
5.3.1. Mass change
HMW-Controls exhibited little dry mass change through the first 15 days of degradation,
after which a linear decrease in mass of 4.8%/day occurred through day 30 (Figure 1A). A
significant (p<0.05) decrease in mass was observed at each time point from day 20 and onward.
Over the first 5 days, the wet mass of these scaffolds decreased significantly (p<0.05) at a rate of
9.4%/day, then increased slightly between days 10 and 20, before gradually declining through
day 35, although none of these later changes was significant (Figure 1B). Both HMW-AH and
HMW-H/AH scaffolds exhibited a small wet mass loss in the first day, followed by a relatively
linear 6.5%/day wet mass increase through day 30 to a maximum of 273% of original mass. At
day 35, scaffolds fell apart upon handling and measurable mass decreased to 93% of the initial.
HMW-H scaffolds had a larger wet mass loss of 37% (p<0.05) after 1 day, and between days 5
and 25, an 8.6%/day mass increase occurred. A plateau was reached between days 25 and 30
prior to a large decrease in mass at day 35. After a 1-day dry mass loss of 12%, HMW-AH
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scaffolds lost mass at a rate of 1.7%/day until day 10. Mass loss resumed at day 15 and
continued at a rate of 0.87%/day until day 30. HMW-H/AH scaffolds had a dry mass loss of 26%
after day 1, and no significant mass change followed through day 30. Similarly, HMW-H scaffolds
exhibited a large initial dry mass loss of 38% after 1 day, and no significant subsequent mass loss
occurred until day 30 (p<0.05).
LMW-Controls exhibited a gradual dry mass decrease to 89% after 8 days, after which
the mass decreased linearly at a rate of 3%/day through day 30 (Figure 5.1C). LMW-Control wet
mass rapidly increased to 193% through the first 5 days, then sharply declined and fluctuated
around 150% through day 16 (Figure 5.1D). Beyond day 16, a linear mass loss of 7%/day
occurred through day 30. LMW-AH scaffolds decreased steadily in dry mass at a rate of 5%/day
for the first 8 days, followed by a brief plateau through 12 days, and terminating with a linear
mass loss of 2%/day through day 30. LMW-AH wet mass increased for the first 5 days and
plateaued, fluctuating around 150% through day 16. After day 16, a mass loss of 7%/day
occurred through day 30.
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Figure 5.1. Mass loss of ISIs. Remaining dry mass of A) HMW scaffolds and C) LMW scaffolds.
Remaining wet mass of B) HMW scaffolds and D) LMW scaffolds. Data are mean +/- standard
deviation (n=3).
5.3.2. Microarchitecture
The microarchitecture of HMW-Controls changed dramatically throughout the first 15
days of degradation, leading to collapse, while HMW ISIs containing PBAE additives possessed a
more uniform pore structure and swelled visibly throughout the 15 day period (Figure 5.2). After
1 day, HMW-Controls were composed of a dense solid phase with large, homogeneously
distributed spherical pores. By day 5, some large pores remained in the core of the scaffold,
while most were present near the edges and were oriented radially. By day 10, the radial pores
were more numerous, surrounding the dense core, and by day 15, the scaffolds had collapsed.
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HMW-H scaffolds possessed a uniformly porous microstructure by day 1, and there were little
microstructural changes until day 15, when noticeable swelling had occurred. HMW-AH and
HMW-H/AH scaffolds both initially possessed porous networks with radiopaque regions inside
these pores, which is indicative of non-degraded PBAE material (Figure 2, arrows). By day 5,
scaffolds were noticeably swollen, and there was little evidence of non-degraded PBAE material,
resulting in a uniformly porous microstructure; the swelling increased progressively through day
15. None of the scaffolds containing PBAE additives collapsed within the 15-day period.
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Figure 5.2. 3-D micro CT reconstructions, bisected, of HMW ISIs containing no additives (Control)
or 10% PBAE particles (H, AH, or H/AH). White indicates material present in the cut plane. Arrows
indicate solid material within pores
HMW ISIs generally increased in both porosity (Figure 5.3A) and volume (Figure 5.3B) as
they degraded. Specifically, HMW-Controls initially possessed 24% porosity, which increased to
a maximum of 54% at day 10, and then declined slightly to 46% by day 15. All PBAE-containing
scaffolds steadily increased throughout the 15-day period, with initial porosities ranging from
42% (HMW-AH) to 55% (HMW-H). All PBAE-containing ISIs possessed significantly higher
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porosities than HMW-Controls at all time points (p<0.001). Among PBAE-containing ISIs, only
HMW-AH at day 1 differed significantly in porosity from others. Scaffold volume, normalized to
initial mass, showed that HMW-Controls increased slightly in volume by day 5 before gradually
declining (Figure 3B), and had significantly lower volume than all PBAE groups throughout
degradation (p<0.01). HMW-H exhibited an initial decrease in scaffold volume between days 1
and 5, followed by a linear increase beyond the initial volume by day 15. Both HMW-AH and
HMW-H/AH generally increased in volume throughout the 15 day period.
Accessible volume was measured for various simulated penetrating sphere diameters
ranging from 12 µm to 120 µm, and the volume accessible by a 24 µm sphere was compared
between groups over 15 days (Figure 5.3C). This diameter approximates the size of the
progenitor cells that may migrate into these pores [251, 252]. At day 1, HMW-Control and
HMW-AH possessed significantly lower accessible volume than HMW-H and HMW-AH samples
(p<0.01). At day 5 and beyond, all PBAE-containing ISIs possessed similar accessible volumes,
which increased from 34-38% at day 5 to 65-78% by day 15. From days 5 through 15, controls
had significantly lower accessible volume (p<0.001). Accessible surface area was normalized to
initial scaffold mass, and measured using the same 24 µm penetrating sphere size (Figure 5.3D).
The trends for accessible surface area were similar to accessible volume, with HMW-Control and
HMW-AH initially possessing significantly lower values than HMW-H and HMW-AH (p<0.01).
Controls remained significantly lower than all other groups for each subsequent time point
(p<0.001). HMW-AH increased linearly in accessible surface area through day 15 before
plateauing, while both HMW-H/AH steadily increased in accessible surface area throughout
degradation. HMW-H remained relatively unchanged between days 1-5 before increasing
linearly through day 15.
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Figure 5.3. Microarchitecture of HMW scaffolds throughout degradation. A) Porosity and B)
mass-normalized volume of scaffolds, evaluated using micro CT. Accessibility of C) scaffold
volume and D) mass-normalized surface area to a simulated 24 µm sphere. Data are mean ±
standard deviation (n=3).
5.3.3. Interfacial strength and mechanical properties
The interfacial strength in cylindrical gelatin molds, as measured by maximum push-out
force, decreased over 15 days for HMW-Controls and increased over the same period for HMWAH (Figure 5.4). For HMW-Controls, at 3 days, the interfacial strength was 1.2 kPa, and
decreased relatively linearly until it was significantly reduced to 0.5 kPa by day 12 (p<0.05). The
interfacial strength of HMW-AH samples increased significantly from 4.7 kPa at day 3 to 8.8 at
day 6 (p<0.01), and the interfacial strength continued to increase, although not significantly, to
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11 kPa by day 15. At every time point, the interfacial strength of HMW-AH significantly exceeded
that of HMW-Controls (p<0.001).
LMW samples exhibited a less dramatic difference between AH and Control groups
(Figure 5.4). LMW-Controls remained significantly higher than HMW-Controls and lower than
HMW-AH at all time points (p<0.01), with interfacial strengths ranging from 2.7 to 5 kPa. LMWAH interfacial strength increased from 5.2 at day 3 to 8.7 by day 9, then decreased down to 5.3
by day 15. LMW-AH samples possessed significantly higher interfacial strength than LMWControls for the first 12 days tested (p<0.005), and the interface remained similar to HMW-AH
samples until days 12 and 14, which were both significantly lower than corresponding HMW-AH
interfacial strengths (p<0.01).
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Figure 5.4. Interfacial strength measured from push-out tests on cylindrical samples within
gelatin molds. Data are mean ± standard deviation (n=3).
Both HMW-Control and HMW-AH cylindrical samples exhibited initial and 30-cycle
compressive moduli that remained unchanged through the first 9 days, followed by a decrease
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through day 15 (Figure 5.5A). For HMW-Controls, initial modulus ranged between 48 and 61
MPa through the first 12 days, and then a significant decrease to 25 MPa occurred (p<0.01).
Significant changes in HMW-AH samples were detected only between day 15 and days 6 or 9
(p<0.05), and over the 15-day period, these moduli ranged from a minimum of 14 MPa at day 15
to 29 MPa at day 9. The 30-cycle modulus did not change in HMW-Controls for the first 9 days,
with moduli ranging from 94 to 102 MPa. Significant decreases occurred at day 12, to 58 MPa,
and at day 15, to 17 MPa (p<0.0001). Modulus ranged from 24 MPa at day 3 to 34 MPa by day 9,
and then decreased significantly to 14 MPa by day 15 (p<0.001). The ratio of the initial to the 30cycle modulus did not change significantly throughout the 15 day period in HMW-AH samples,
and it ranged from 0.95 at day 15 to 1.16 at day 9 (Figure 5.5B). In HMW-Controls, the modulus
ratio ranged from 1.67 to 1.88 over the first 9 days, and then decreased significantly to 1.2 by
day 12 and 0.7 by day 15 (p<0.01).
HMW-Controls and HMW-AH samples increased in resilience between days 3 and 6
before declining through day 15, and HMW-Controls exhibited the highest initial resilience and
the lowest 30-cycle resilience (Figure 5.5C). Resilience from the initial compression cycle of
HMW-Controls increased significantly from 1 J/m3 at day 3 to 3.1 J/m3 at day 6 (p<0.0001), and
then decreased significantly at day 12 to 0.97 J/m3 (p<0.0001). The 30-cycle resilience followed
the same trend, with 0.35 J/m3 at day 3, which increased significantly to 0.9 J/m3 by day 6, then
dropped significantly to 0.25 J/m3 by day 12 (p<0.001). The ratio of the initial to the 30-cycle
resilience through the first 12 days ranged from 0.26 to 0.33, and a significant decrease occurred
between days 9 and 15, down to 0.15 (p<0.05) (Figure 5.5D). HMW-AH initial resilience
increased significantly between days 3 and 6, from 0.73 to 1.7 J/m3 (p<0.001). The resilience did
not change until day 15, when a significant decrease occurred from 1.53 J/m3 at day 9 to 0.79
J/m3 at day 15 (p<0.01). The 30-cycle modulus of HMW-AH samples increased significantly from
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0.46 J/m3 at day 3 to 1.28 J/m3 at day 6 (p<0.0001), with subsequent significant decreases at day
12, to 0.83 J/m3 (p<0.01), and at day 15, to 0.52 J/m33 (p<0.05). The ratio of these two resilience
values for HMW-AH samples did not change significantly throughout the 15 day period.
LMW-Controls possessed uniformly higher ratios of initial to 30-cycle modulus at each
time point compared to LMW-AH, though this difference was only significant at days 3 and 12
(p<0.05) (Figure 5.5F). Similar to HMW samples, LMW-AH samples exhibited an initial to 30cycle modulus ratio ranging from 0.94 to 1.13. While LMW-Control initial modulus increased
steadily from 3.2 to 8.6 MPa between days 3 and 12, LMW-AH initial modulus fluctuated from
3.7 to 12 MPa, with a maximum at 9 days and a minimum at 12 days, resulting in no clear trend
(Figure 5.5E). The initial resilience of both LMW-AH and LMW-Control was highest at day 12, and
in all cases, the 30-cycle resilience was lower than the initial value for both LMW-AH and LMWControl (Figure 5.5G). However, the ratio of initial to 30-cycle resilience of LMW-AH, ranging
from 0.46 to 0.56, was significantly higher at every time point than the same ratio for LMWControl (p<0.05), which ranged from 0.15 to 0.33 (Figure 5.5H).
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Figure 5.5. Mechanical properties of HMW (A-D) and LMW (E-H) cylindrical implants subjected
to 30 cycles of 1% compressive strain at 1 Hz. A,E) Initial and 30-cycle modulus. B,F) Ratio of
initial to 30-cycle modulus. C,G) Initial and 30-cycle resilience. D,H) Ratio of initial to 30-cycle
resilience. Data are mean ± standard deviation (n=3).
5.3.4. Drug Release
HMW scaffolds loaded with simvastatin released simvastatin over 90 days, and scaffolds
containing PBAE microparticles produced release profiles with distinct regions of different
release rates (Figure 5.6A). HMW-Controls exhibited a significantly higher 1-day burst of 36%
(p<0.001), compared to all PBAE-containing groups, which all had a burst of 6% or less. HMWControls exhibited a declining daily release rate over the course of 40 days, with residual
simvastatin released over the last 40 days as scaffolds completely degraded. HMW-H exhibited a
relatively linear release rate of 1%/day through day 30, followed by a period of minimal release
through day 60. HMW-AH had a release rate of 2.8%/day for the first 13 days, followed by a
period of 1%/day through day 30 and then 0.25%/day through day 50. HMW-H/AH had release
rates of 2.1%/day through day 13, 1%/day through day 30, and then 0.2%/day through day 50.
Beyond day 60, the remaining drug was released through day 90 as scaffolds completely
degraded.
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LMW scaffolds released simvastatin through 30 days, and AH6 microparticle additives
reduced burst for each formulation (Figure 5.6B). LMW-Controls had 47% burst followed by a
roughly linear release rate of 2.1%/day through day 30. The burst was reduced to 21% for
40LMW-Controls, after which the release rate steadily declined through day 30. There was no
difference in simvastatin release kinetics between LMW-AH scaffolds containing simvastatin
alone or doxycycline and simvastatin together. Both LMW-AH and 40LMW-AH scaffolds had no
appreciable burst, and linear release rates ranged from 2.3 to 2.5%/day through days 24 and 26,
respectively. At day 24 or 26, the release rate increased to 10%/day until all drug was released.
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Figure 5.6. Simvastatin release from A) HMW and B) LMW scaffolds. D+S indicates that scaffolds
were co-loaded with simvastatin and doxycycline. Data are mean ± standard deviation (n=3).
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Doxycycline exhibited similar release patterns from both HMW (Figure 5.7A) and LMW
ISIs (Figure 5.7B), with no difference observed between PBAE-containing scaffolds and controls.
Pre-loading doxycycline into PBAE microparticles resulted in a 1-day burst similar to controls,
but with significantly more drug released over the remainder of the week. In all cases where the
antibiotic was not pre-loaded into AH6 microparticles, the release plateaued within one or two
days, and drug was released incrementally for the remainder of the monitored period. In all
HMW ISIs tested, release plateaued at approximately 70% of total drug, and pre-loaded
doxycycline released an additional 28% over the following 6 days. In LMW ISIs, the plateau
ranged from 86-95% for 30% PLGA and from 63-74% in 40% PLGA. 40% LMW PLGA ISIs were
tested with pre-loaded doxycycline, and after an initial 63% burst, release continued up to 87%
by day 7.
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5.4. Discussion
PBAE additives act as both porogens and drug delivery vehicles within the solid PLGA ISI
matrix. As porogens,the 1-day mass loss of HMW-H and HMW-H/AH scaffolds indicated
complete degradation of H6, which has an expected degradation time of 4-8 hours [70], while
both HMW-AH and LMW-AH scaffolds exhibited a gradual mass loss through 10 days, which is
twice the 5 day in vitro degradation time of AH6 PBAEs [253]. The difference is probably due to
the PLGA matrix both limiting the accessibility of water to the embedded PBAE microparticles
and physically restraining them from swelling, thus slowing degradation [80, 254]. There is
evidence that PBAE swelling is restricted by comparing the microCT cutplanes and implant
volumes between groups, in which HMW-H, which contains the most hydrophilic PBAE, swelled
more gradually and to a smaller degree than HMW-H and HMW-H/AH formulations.
Theoretically, H6 should achieve greater maximum swelling than AH6, and the maximum
swelling point should occur at 4 hours and 36 hours, respectively [255]. HMW-H scaffolds likely
had delayed degradation of the PBAE as well, however, the daily sampling frequency would not
detect a difference unless the degradation period of H6, which typically degrades in 4-8 hours
[70], was prolonged beyond 24 hours. The failure of HMW-Controls to swell beyond their initial
mass suggests that the loss of NMP during precipitation exceeded the water uptake of the
scaffolds. Conversely, LMW-Controls were capable of entrapping water in the core of the
scaffolds due to their less hydrophobic nature, and the rapid decrease in wet mass after day 3
was caused by the fragile PLGA skin rupturing, allowing the entrapped buffer to leak out.
Interestingly, all HMW scaffolds containing PBAE microparticles swelled up to 250% of their
original mass over a period of 30 days, while comparable LMW scaffolds swelled to a maximum
of 150%. Again, LMW scaffolds were prone to rupture, which would allow water to escape,
while the HMW scaffolds remained structurally sound as they swelled, and therefore
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maintained a larger water capacity. Prior research on similar systems containing porogens such
as sucrose or sodium chloride did not show such a dramatic mass changes [248], which suggests
that the swelling behavior of PBAE hydrogel particles has a more profound effect on water
uptake and retention than traditional porogens.
PBAE microparticles also influence macro- and microstructural changes of ISIs as they
degrade. HMW-Controls possessed surface-adjacent smaller pores and centrally-located
macropores, which is typical of these implants because PLGA at the surface tends to precipitate
rapidly, while the interior precipitates more gradually, allowing voids to coalesce [141]. PBAE
microparticles caused the ISIs to adopt a porous network with no difference between surface or
central pore sizes, because the homogeneous distribution of hydrogel microparticles acted as a
template for a uniform PLGA microstructure. This hypothesis is supported by the rapid swelling
and increase in accessible volume observed in all PBAE-containing ISIs. The lack of collapse in
HMW-AH, -H, or H/AH implants implies that these homogeneously distributed hydrogel particles
also play a role in stabilizing the implant structurally. In HMW-Controls, the largest pores
collapsed, whereas in PBAE-containing scaffolds, with their uniform microstructures, were able
to distribute stresses throughout the PLGA matrix and did not collapse. It has been previously
demonstrated that varying the size and distribution of pores can dramatically alter mechanical
properties of materials [256, 257]. The lattice-like PLGA network of PBAE-containing implants
may also help explain the sustained mechanical resilience observed in HMW-AH implants even
after the degradation period of the PBAE had passed. The increased porosity and accessible
surface area of PBAE-containing ISIs offers many advantages when considering PLGA ISIs as
potential scaffolds rather than simply drug delivery devices. In pre-formed PLGA scaffolds, larger
accessible volume and surface area provides more opportunity for tissue ingrowth, and it is
anticipated that PLGA ISIs will behave similarly in future cell culture or in vivo testing.
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A persistent issue with antibiotic-releasing implants in periodontal applications is that
the implant is not secure inside the periodontal pocket, which can lead to small pieces breaking
off as the implant moves within the space [258]. Here, push-out forces were used to measure
the interfacial strength between the implant surface and a simulated tissue pocket. The
opposing trends observed in push-out force for HMW-Control compared to HMW-AH samples
indicate that swelling of AH hydrogels can improve space-filling and pocket retention of
implants. Even at the initial 3-day measurement, HMW-AH samples had significantly higher
interfacial strength than controls, and this difference became even more pronounced as the
incubation period increased. Although HMW PLGA does swell to a small degree as it degrades,
this behavior is offset by the shrinkage of the implant during the precipitation phase, and the
net result is that the interfacial strength remains negligible. On the other hand, AH hydrogels
were observed to swell beyond 200% of their initial mass within 2 days in PBS (data not shown),
and although this effect is probably muted due to the physical constraint within the PLGA
matrix, there is enough of an effect to provide 4 to 10-fold higher interfacial strength than
controls. Preliminary studies also showed no measurable adhesion between the gelatin surface
and the implants (data not shown), so any differences in interfacial strength should be solely a
result of the superior space-filling due to swelling of HMW-AH implants. LMW-AH scaffolds
exhibited a similar benefit compared to LMW-Controls, though this difference was less
pronounced due to the natural swelling behavior of LMW-Controls, which increased interfacial
strength, and the rapid degradation of material, which caused both LMW-Controls and LMW-AH
to decrease in strength over the 15 day period. A scaffold that expands to fill its injection site as
it solidifies is less likely to cause irritation due to movement within the pocket. Furthermore,
more contact area between the implant and the tissue means that the released drug has a
shorter path to enter the gingival tissue, and it has a smaller likelihood of being washed away

103

due to fluid exchange in the crevicular fluid. Unfortunately, little information is available on the
magnitude of stresses experienced within gingival soft tissue, although it is widely reported that
the periodontal ligament is the soft tissue responsible for transmitting chewing force between
the tooth and the underlying alveolar bone [259, 260]. Measurements of the stress in oral
mucosal tissues under typical bite forces of denture wearers suggested that these tissues
experiences compressive stresses ranging from 5 to 40 kPa during chewing [261]. According to
these values, HMW-AH ISIs have initial interfacial strengths within that range, and within 6 days
the interfacial strength exceeds the stress generated by a soft bite. HMW-Controls at every time
point possessed interfacial strengths 1-2 orders of magnitude lower than these stress ranges.
This data suggests that patients receiving HMW-AH ISIs may be able to chew food shortly after
receiving treatment without danger of loosening the implant, while controls, which approximate
clinically available treatments, are easily loosened and dislodged. This swelling-based, spacefilling approach is an alternative to other avenues that seek to reduce detachment by improving
the adhesion between the polymer surface and surrounding tissue [249]. While the bioadhesion
approach was observed in the first several hours following implantation, the PBAE-containing
ISIs were demonstrated to improve pocket retention through a 15-day period. An interesting
approach for future studies may be to incorporate both bioadhesive and swelling additives in
order to provide acute attachment followed by prolonged space-filling.
Although these periodontal ISIs are not designed as load-bearing structures, they are
subject to stresses, primarily due to chewing, which typically occurs at frequencies between 0.1
and 1 Hz in humans [262]. The gelatin molds used in push-out studies had similar compressive
modulus compared to gingival tissues in order to simulate a periodontal pocket (data not
shown) [250]. It has been proposed that less stiff implants may reduce irritation due to the
presence of material within the periodontal pocket [263]. PLGA deformed plastically and
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became stiffer under compression even at low strains and only 30 compression cycles, while the
modulus of HMW-AH and LMW-AH samples remained unchanged, indicating that PBAE
additives preserve elasticity. In the commercially available Atridox® system, a dressing or
adhesive is used to keep the implant in place, but there is also the concern that repeated
compression cycles can cause the implants to break apart, allowing pieces of material to cause
local irritation, or escape the periodontal pocket [264, 265]. Therefore, flossing and brushing are
discouraged for up to a week following implantation, and patients are told to expect small
pieces of material to break off [265]. Although neither control nor PBAE-containing ISIs broke
apart during the timeframe or compression cycles observed, the 30-cycle modulus of HMWControls was reduced dramatically between 9 and 15 days, and this difference would likely
become more pronounced as time or compression cycles increased. HMW-AH and LMW-AH
samples were less stiff and retained their modulus throughout cyclic compression, which
suggests they are more suitable to withstand the dynamic mechanical environment of the
periodontal tissue. HMW-Controls and LMW-Controls were more resilient during the initial
compression cycle, yet they were consistently less resilient than corresponding AH-containing
implants after 30 cycles, indicating that the PBAE hydrogel component helps preserve resilience.
The lack of change for both modulus and resilience after cyclic loading is promising for the
development of more mechanically suitable implants for the periodontal pocket. Dynamic
mechanical analysis is required to assess viscoelastic properties for full lifespan of the implant,
but this short-term cyclic compression data suggests that the addition of only 10% hydrogel
particles can greatly improve the durability of these implants. As mentioned previously, the
addition of PBAE microparticles led to a lattice-like PLGA microstructure, which should
theoretically provide more resilience than the heterogeneous structure of the controls because
there are no macropores, which appear to be the source of collapse in controls. Oral soft tissues
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have compressive moduli ranging from 0.2 to 8 MPa [250, 266], and typical dental materials
used to fill these soft tissues after extractions or other procedures have moduli on the order of
1-20 MPa [267], which are both similar to the compressive properties of ISIs developed here.
Simvastatin release kinetics from both HMW and LMW ISIs were highly dependent on
PBAE microparticle content. The larger burst in controls can be attributed to simvastatin
dissolved in the NMP phase being rapidly lost during solvent exchange, which has been
previously reported [81]. Because PBAEs swell even more freely in organic solvents, such as
NMP, acetone, and ethanol, than in water, PBAE microparticles become swollen with NMP and
simvastatin during the mixing phase prior to injection. These swollen microparticles act as an
additional diffusive barrier to reduce initial burst, and once the initial hardening of the scaffold
surface has occurred, simvastatin release is governed by both diffusion and PBAE degradation.
The degradation profile of AH6 microparticles is reflected in the accelerated release rate of AH
and H/AH scaffolds through day 13. The release profile of HMW-H/AH closely approximates the
average of the HMW-H and HMW-AH curves, which suggests that the two hydrogels contribute
independently to simvastatin release kinetics, and the results of their contributions are additive.
Simvastatin release kinetics were more strongly affected by PBAE microparticle content in 30%
LMW PLGA scaffolds than in 40% LMW PLGA scaffolds, and this difference is attributable to
multiple factors. First, the higher PLGA content formulation is more viscous, which allows more
rapid formation of a protective “skin” that slows solvent exchange and thus burst release.
Second, 40% LMW ISIs contain more PLGA for equivalent injected masses when compared to
30% LMW ISIs, which provides more polymer volume to entrap simvastatin, further limiting
burst. Interestingly, AH6 degradation did not appear to accelerate simvastatin release in LMW
scaffolds as dramatically as it did in HMW scaffolds for the first 10 days. This may be due to the
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faster degradation time and relatively higher hydrophilicity of LMW PLGA, which allows faster
simvastatin release from the PLGA phase and masks the contribution of AH6-mediated release.
Release kinetics of freely-mixed doxycycline from HMW and LMW ISIs were unaffected
by the addition of PBAE microparticles, however pre-loading doxycycline into AH6 microparticles
provided a measure of control. The lack of additional doxycycline release after the initial burst in
freely-mixed cases is probably due to the entrapment of remaining drug in the PLGA phase, and
because doxycycline is substantially more hydrophilic than simvastatin, it has low mobility
through the hydrophobic PLGA matrix. This plateau effect is undesirable for antibiotic delivery,
because bacteria surviving the initial burst will be free to re-colonize. By pre-loading doxycycline
into AH6 PBAE microparticles, the initial burst was followed by continuous release of remaining
drug through 1 week, which is consistent with systemic doxycycline regimens of 1 week
following scaling and root planing.
5.5. Conclusions
PLGA ISIs formulated with PBAE microparticle additives provide multiple advantages
over existing periodontal ISIs. These composite ISIs are more resilient and are retained more
firmly in simulated gingival tissue than PLGA alone, so there will be a lower risk of the implant
deforming, loosening, and breaking apart prematurely, which is a concern with existing systems.
Additionally, PBAE microparticles offer a secondary means of controlling drug release kinetics,
and multiple drugs with independent release profiles can be delivered, instead of the singledrug systems that are currently available. Future studies will focus on the potential of these
PBAE-containing ISIS to act as scaffolds for tissue regeneration, because the high porosity and
open pore network is suitable for tissue ingrowth.

107

Chapter 6 Summary and Conclusions
In this dissertation, hydrogel and hydroxyapatite additives were used to improve the
properties of PLGA ISIs, and provide an early proof of concept that these materials can also
serve a role as scaffolds rather than pure drug delivery devices.
First, the orthopedic potential of composite PLGA/PBAE/HA ISIs was investigated. Both
simvastatin and clodronate were released with reduced burst compared to controls, which
demonstrated that drug release can be controlled independently of traditional techniques that
modify the precipitation rate. These results suggest that a modular system can be developed,
where a single PLGA solution can be easily modified to provide tailored release kinetics simply
through the addition of HA and drug-loaded PBAE microparticles. Hydroxyapatite was then
shown to control mechanical properties of these ISIs, and this information was used to develop
a formulation that was mechanically similar to healthy trabecular bone. Importantly, the
proposed system would be locally injectable into the intertrabecular space within the femoral
head, which eliminates the need for invasive surgery and removal of tissue. Instead, the ex vivo
injections showed the feasibility of this system to mechanically support bone within the femoral
head while the drug release component takes effect. The orthopedic scaffolds developed in
Chapters 3 and 4 have the potential to fill an important role in the treatment of osteonecrosis,
because existing techniques are invasive and have limited effectiveness once the disease has
weakened the bone enough to cause collapse.
PBAE hydrogel microparticles were also shown to improve PLGA ISIs for soft tissue
applications, specifically in the oral gingiva. ISIs capable of co-delivery of doxycycline for 1 week
and simvastatin for 30 to 90 days were developed, which has implications in cases of advanced
periodontitis where extensive bone loss has occurred. Additionally, the PBAE additives improved
interfacial strength in a simulated periodontal pocket due to swelling, and were responsible for
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reducing stiffness and increasing durability of solidified ISIs. Ultimately, the PBAE-containing ISIs
are a more suitable match for soft tissue, and also provide dramatically more accessible volume
and porosity, which is advantageous for tissue ingrowth.
From a tissue engineering perspective, current PLGA ISIs are nonfunctional as scaffolds,
with closed pores, a heterogeneous microarchitecture, and poor mechanical properties. In
preformed, implantable PLGA scaffolds, additives are frequently used as porogens or to
facilitate drug delivery, and that approach was employed here to improve numerous properties
of PLGA ISIs. The resulting PBAE-containing ISIs are a versatile drug delivery platform with
tremendous potential as “all in one” treatments that can be adapted to different tissues simply
by modifying the additives.

Copyright © Paul Daniel Fisher 2014
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